

From *Eberthella typhi* to *Salmonella Typhi*: The Fascinating Journey of the Virulence and Pathogenicity of *Salmonella Typhi*

 Ritika Chatterjee,[#] Atish Roy Chowdhury,[#] Debapriya Mukherjee,[#] and Dipshikha Chakravortty*


Cite This: ACS Omega 2023, 8, 25674–25697




Read Online

ACCESS |

Metrics & More

Article Recommendations

ABSTRACT: *Salmonella Typhi* (*S. Typhi*), the invasive typhoidal serovar of *Salmonella enterica* that causes typhoid fever in humans, is a severe threat to global health. It is one of the major causes of high morbidity and mortality in developing countries. According to recent WHO estimates, approximately 11–21 million typhoid fever illnesses occur annually worldwide, accounting for 0.12–0.16 million deaths. *Salmonella* infection can spread to healthy individuals by the consumption of contaminated food and water. Typhoid fever in humans sometimes is accompanied by several other critical extraintestinal complications related to the central nervous system, cardiovascular system, pulmonary system, and hepatobiliary system. *Salmonella* Pathogenicity Island-1 and *Salmonella* Pathogenicity Island-2 are the two genomic segments containing genes encoding virulent factors that regulate its invasion and systemic pathogenesis. This Review aims to shed light on a comparative analysis of the virulence and pathogenesis of the typhoidal and nontyphoidal serovars of *S. enterica*.



INTRODUCTION

Salmonella enterica, a Gram-negative food-borne pathogen causing enteric fever and gastroenteritis, is one of the significant reasons for thousands of mortalities worldwide.^{1–3} *Salmonella* is divided into two species: *Salmonella bongori* and *Salmonella enterica*.⁴ The species *enterica* is further categorized into six subspecies: *enterica*, *salamae*, *diarizonae*, *indica*, *arizonae*, and *houtenae*, with about 2700 serovars based on surface antigens. Almost 1500 serovars of *S. enterica*, which includes Typhimurium and Enteritidis, can cause infection in humans and animals after being consumed with contaminated food and water.⁵ On the contrary, *S. bongori* can only infect cold-blooded animals. Among all the serovars, the *S. enterica* serovar Typhi (*S. Typhi*) infection is strictly restricted to humans (known as typhoid fever). The host-restriction of *S. Typhi* is attributable to a 5% reduction of its genome due to the pseudogenization of 200–300 genes.⁶ Other typhoidal serovars, such as *S. Paratyphi A*, *B*, and *C*, are also associated with systemic infection in humans, known as paratyphoid fever.⁷

The nontyphoidal serovar (NTS) *Salmonella* Typhimurium (*S. Typhimurium*) can infect a wide range of hosts, including humans, plants, and animals.^{8,9} Other serovars of *S. enterica*, such as Enteritidis, Gallinarum, and Pullorum, are responsible for the outbreaks in poultry industries.^{10,11} Additionally, certain strains of *Salmonella*, such as sequence types ST313, ST34 (for Typhimurium), and ST11 (for Enteritidis), are associated with invasive bloodstream infection in humans.¹² It

has been reported that the multidrug-resistant *S. Typhimurium* ST313 causes bloodstream infection in adults and children with 20–25% fatality in sub-Saharan Africa.^{13,14} *Salmonella* infection in humans can also cause extra-intestinal complications related to the central nervous system (3–35%), pulmonary system (1–6%), cardiovascular system (1–5%), and hepatobiliary system (1–26%).¹⁵ Owing to the excessive use of antibiotics, the rapid emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains of *S. Typhi* made *Salmonella* infection extremely difficult to treat.¹⁶ To study the *in vivo* pathogenesis of *S. Typhimurium*, many susceptible mouse strains, such as BALB/c and C57BL/6, mimicking the symptoms of typhoid fever in humans are extensively used.^{17,18} However, very few suitable models are available to study the *in vivo* pathogenesis and disease progression of *S. Typhi*. Additionally, a reduction in the size of its functional genome by either pseudogene formation or the absence of specific genes made our understanding of typhoid fever extremely difficult. Hence, a comprehensive discussion is required to explain the complexity of the interaction between

Received: April 9, 2023

Accepted: June 30, 2023

Published: July 14, 2023





Figure 1. A timeline history of typhoid fever.

S. Typhi and the human host. This Review will revisit the history, global epidemiology, pathogenicity, virulence, and extra-intestinal complications related to typhoid fever and recent developments in these research domains.

HISTORY OF TYPHOID FEVER AND GLOBAL EPIDEMIOLOGY

History of Typhoid Fever. It is well established that *Salmonella* has existed and evolved on Earth with a long, multihued, and entrancing history of evolution. The name typhoid fever was derived from the Greek word “τυφος”, which stands for smoke, stupor, and obscurity associated with the diseased person, as they experienced stupor and neuropsychiatric symptoms in severe infection. Even though the description of typhoid fever was first made as early as 1643 by Sir Thomas Willis, it was often confused with typhus. However, typhus is a flea-borne illness caused by *Rickettsia typhi* and *Rickettsia felis*, with symptoms ranging from fever, headache, rash, and hepatitis to diverse organ prognosis.¹⁹ A brief timeline of the history of typhoid fever, therapeutic interventions, and vaccine development is depicted in Figure 1.

In the context of typhoid vaccine designs, Vi capsular polysaccharides (Vi CPS) require only a single administration dose and elicits low reactogenicity. However, Vi CPS is a T-independent type 2 (Ti2) antigen that cannot be immunogenic in infants. New and future generations of vaccines include Vi glycoconjugate, O-antigen glycoconjugate, recombinant proteins, and proteins isolated and purified from whole *Salmonella*. These vaccine development advancements have improved the protection against *Salmonella*, allowing low reactogenicity and better memory response.²⁰ As important as history is to understand this ancient pathogen, it is equally imperative to delve into the current global burden on healthcare and

economies. Therefore, we will discuss global epidemiology in the next section.

Global Epidemiology. The overall burden of foodborne disease is enormous, accounting for 33 million deaths annually. Almost 1 in 10 people fall ill with foodborne illness, and *Salmonella* is one of the four predominant causes of diarrheal diseases globally. South-central Asia and Southeast Asia have the highest incidence of illness, followed by Latin America and Africa. In 2017, typhoid and paratyphoid fever alone accounted for 14.3 million illnesses globally. The same report suggested that S. Typhi caused around 76.3% of enteric fever, with a global fatality rate of 0.95% in 2017. Around 14.1% of total typhoidal cases are accounted for Southeast Asia, East Asia, and Oceania super-regions, followed by 12.1% of total typhoidal cases reported from sub-Saharan Africa.²¹ The available general case reports on the prevalence of Typhoidal fever in sub-Saharan Africa and Latin America are limited. However, a recent systemic review of sub-Saharan African cases suggests that the incidence of occurrence in African countries is highly heterogeneous and increases with better surveillance of healthcare systems with time.²² In Latin America, typhoid is more prevalent than paratyphoid.²¹

Typhoid and paratyphoid fevers are pervasive in young children (especially under the age of 5) and older adults in lower-income countries and are often life-threatening. Enteric fevers are endemic in developing countries, where adequate sanitation and acute clean water shortages hold paramount public health concerns.^{23,24} Even though typhoid and paratyphoid clinical symptoms are indistinguishable, the epidemiology, susceptibility to antibiotics, and geographical distributions are distinct.^{25,26} Paratyphoid to typhoid fever cases are higher in developed areas such as Central Europe (90.7%) and high-income subcontinents such as Australia, Asia Pacific, North America, and Western Europe. On the other hand,

Central Asia, Eastern Europe, Latin America, North Africa, Middle East, South Asia, Southeast Asia, East Asia, Oceania, and Sub-Saharan Africa account for approximately 53–98% of typhoid fever of the reported enteric fever cases.²¹

A study from Cambodia showed that approximately 42.9% of isolates of *S. Typhi* demonstrated MDR, whereas only 11.5% of *S. Paratyphi* isolates displayed increased resistance to ciprofloxacin, and none of the isolates of *S. Paratyphi* exhibited MDR.²⁶ Typhoidal and paratyphoid outbreaks in developed countries are usually linked to travel history to endemic areas.²⁷ In the past few years, the rate of *S. Paratyphi* A infection has surged, accounting for nearly 50% of all cases, especially in the Southeast Asian population.^{24,28} A few studies also point out that genetic factors influence susceptibility to enteric fever. VAC14 is a phosphoinositide-regulating protein, and single nucleotide polymorphism (SNP) in VAC14 renders the host with an increased *S. Typhi* susceptibility. VAC14 SNP increases plasma membrane cholesterol, resulting in increased docking of *S. Typhi* to host cells.²⁹ Studies from Jakarta, Indonesia, demonstrate that the gastric mucus lining expresses cystic fibrosis transmembrane conductance regulator (CFTR), which has been shown to act as adherent and facilitate the entry of *S. Typhi* but not *S. Typhimurium* into intestinal epithelial cells.³⁰ Therefore, mutations in CFTR (such as F508del and IVS8CA) provide some protection against *S. Typhi* infection.³¹ Extraintestinal salmonellosis is strongly associated with the immune states of individuals. Thus, it affects immune-compromised persons.^{32,33}

■ SYMPTOMS AND DIAGNOSIS

The typhoidal and paratyphoidal fevers cannot be clinically differentiated. It takes about 8–14 days of incubation after infection. The incubation period also varies, with a range of 3–60 days. The disease can last from a few weeks to several months, depending upon the initial exposure to the infectious dose and the diagnosis and treatment time. These parameters also govern the subsequent severity of the disease and related complications. However, in NTS the infection is more localized, causing gastrointestinal inflammation. The incubation period for NTS is about 2–3 days, and the disease lasts for 3–7 days and is self-limiting in a healthy host without any underlying conditions.^{34–36} NTS serovars develop severe complications in immune-compromised individuals, such as systemic secondary-site infection, chronic conditions (reactive arthritis and irritable bowel syndrome), and other febrile illnesses.³⁷ We have listed the common and differential typhoidal serovar and NTS infection symptoms for ease of interpretation in Table 1. Clinical diagnosis of typhoid involves a history of the patient's residence and travel (from endemic areas) and the presentation of febrile illness for more than 3 days with gastrointestinal manifestations (pain, constipation, or

diarrhea). The diagnosis is difficult in the first week of disease onset, but recent advancements have made it easier. In the early 21st century, despite the medical advances in developing countries, laboratory diagnosis can be divided into conventional typhoidal diagnosis (bacteriological culture and Widal test) and advanced typhoidal diagnosis (polymerase chain reaction (PCR) based, enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), hemagglutination, and coagglutination). In the subsequent subsections, we will discuss the currently available diagnoses for typhoidal fevers.

Bacterial Culture-Based Diagnosis. The gold standard diagnostic tool for typhoidal serovar and NTS diseases is still culturing stool, blood, and bone marrow samples. The choice of samples, such as body fluids or feces, depends on the type of infection diagnosed early; for example, stool samples are usually taken for NTS infection associated with localized inflammation. However, this technique may become less sensitive once the infection becomes systemic.³⁸ On the case of systemic enteric fevers such as typhoid and iNTS infection, blood or bone marrow is sampled during the first week of fever; later, urine or stool samples are evaluated. Getting culturable *Salmonella* in the first week of symptoms onset is particularly tricky. Thus, diagnostic laboratories perform the test multiple times, and with a large volume of blood the sensitivity of this diagnosis remains only about 40–80%.^{39–41} For genus-level identification, manual methods or automated systems such as MALDI-ToF are used.⁴² *S. Typhi* usually gives weak H₂S production and a negative ornithine decarboxylase upon biochemical aspect identification, whereas *S. Paratyphi* results in negative H₂S, citrate, and lysine reactions.⁴²

Serotyping and Serological Diagnosis. *S. enterica*, being a multiform pathogen, has over 2600 serovars identified to date. Therefore, the serotyping of the clinical isolates plays a significant role in central public health repositories for endemic serovar identification, epidemiological analysis, surveillance, and disease outbreak studies. The *Salmonella* subtyping is conducted according to the White–Kauffmann–Le Minor scheme. The conventional scheme of serotyping of *Salmonella* evaluates the expression of surface antigens such as somatic (O), flagellar (H), and capsular (Vi) antigens. However, the Vi antigen is exclusively present in *S. Typhi*, *S. Paratyphi* C, and *S. Dublin*.⁴³ Based on somatic antigen, *S. enterica* can be divided into 46 serogroups,⁴⁴ and there are 114 individual flagellar antigens, resulting in 2600 serovars.⁴⁵ The old serotyping methods were tedious and time-consuming for typing an isolate. Several new techniques aid the process of identification of *Salmonella* sp. serovars, such as pulsed-field gel electrophoresis (PFGE),^{46,47} ribotyping,⁴⁸ clustered regularly interspaced short palindromic repeat (CRISPR),^{49,50} and multi-locus sequence typing (MLST).^{51,52} The most performed serological diagnosis employs the Widal tube agglutination method. It is one of the primitive methods used for more than a century to diagnose typhoid or enteric fever. In this test, the killed *S. Typhi* and *Paratyphi* A bacteria are scored based on agglutinating antibodies to flagellar (H), LPS (O), and Vi antigens. However, the efficacy of this method is widely questionable due to its cross-reactivity with different serovars and low sensitivity.^{53,54} Reports of cross-reactivities with unrelated diseases like malaria, dengue fever, and brucellosis in enteric fever-endemic areas are prevalent. Despite all of the drawbacks, it is still extensively used in areas lacking public health infrastructure, mainly because of its low cost and ease of use.

Table 1. Symptoms of Typhoid Fever and Non-Typhoidal *Salmonella* Infection (or Salmonellosis)

<i>Salmonella enterica</i> serovar	disease and symptoms
typhoidal (human-restricted) <i>Typhi</i> , <i>Paratyphi</i> , and <i>Sendai</i>	enteric fever, abdominal distention and pain, transient diarrhea or constipation, a maculopapular salmon-colored rash on the trunk
non-typhoidal (broad range) <i>Typhimurium</i> , <i>Enteritidis</i> , <i>Dublin</i> , <i>Newport</i> , et cetera.	gastro-intestinal, abdominal distention and pain, vomiting, inflammatory diarrhea




Figure 2. The course of *Salmonella* infection and long-term carriage. Initially, (A) *Salmonella* preferentially enters M cells, (B) which transport them to the lymphoid cells (T and B) in the underlying Peyer's patches. (C) It can also be taken up by dendritic cells, elongated dendrites through the intestinal epithelial barrier. (D) Once across the epithelium, *Salmonella* serotypes associated with systemic illness enter intestinal macrophages and (E) undergo intramacrophage replication and (F) disseminate throughout the reticuloendothelial system, leading to systemic infections. (G) Further colonization of the gallbladder leads to (H) chronic carriage and the bacterium's shedding through this mechanism. The green background shade depicts the GI tract near the gallbladder opening, and the yellow background depicts the GI tract's intestinal areas.

Based on a similar principle, some commercially available diagnostic tests adopt the detection and even quantification of antibodies in the patient's serum against several *Salmonella* antigens, such as outer membrane proteins or LPS. However, significant drawbacks remain, including low sensitivity (69%) and specificity (79%).^{55,56} Hemagglutination tests are also routinely used in various countries. A report from India has shown that the anti-LPS HA test has a sensitivity of 60% and a specificity of 98.2%.⁵⁷ Similarly, 70% sensitivity and 92% specificity have been reported for the reverse-phase hemagglutination test (RPHA). These tests propose a convenient alternative for the Widal test to detect *S. Typhi* in endemic areas.⁵⁸ Since there is an increasing need for rapid, reliable, and cost-efficient testing for *Salmonella* to meet the need of the current situation, less sensitive detection of bacteria by PCR from blood samples is widely conducted.

Advanced Diagnostic Techniques. The routine bacteriological culture has a 100% specificity and about 54% sensitivity, and the PCR-based ones have about 98.1% specificity and 85.4% sensitivity⁵⁹ in samples from blood and bone marrow for the flagellin gene (*fliC*), Vi, O, and H antigens, *hilA* (an SPI-1 effector), and 23S rRNA, to name a few.^{40,60–70} Another widely used technique is multiplex PCR, which directly identifies gastrointestinal pathogens in clinical stool samples. Although it can target and simultaneously amplify an array of genes,^{71,72} the results still require further testing and validation through culturing for serotype classification. MALDI-TOF-based diagnosis is a newly emerging technique for reliable and rapid detection and typing of bacteria. Two of the FDA-approved MALDI-ToF systems for *Salmonella* detection are the Bruker Biotyper and bioMérieux Vitek MS systems. However, none of them can

detect the serovar.⁷³ Next-generation sequencing (NGS) for diagnostics and bacterial typing using whole-genome sequencing (WGS) has been on the rise late on as well due to a drastic reduction of cost and a significant increase in downstream tools and bioinformatics analysis for sequence assembly and comparative genomics. Apart from the contig arrangements and analysis, WGS data also facilitate identifying SNP and provides us with single-nucleotide changes among *Salmonella* serovars. This approach enables the study of phylogenetic relationships and disease outbreak epidemiology.^{74–76} WGS-based technologies are at the beginning of the exponential phase, and multiple technologies that have low cost, rapid, and reliability for clinical isolate typing are still in the pipeline, further leading to a shift in the current gold standard for clinical and public health sectors in phylogenetic relationship, origin of evolution, epidemiological, and geographical analyses of newly emerging and endemic serovars.

■ MODELS TO STUDY SALMONELLA INFECTION

S. Typhi is adapted to be highly specific to human hosts. Therefore, there are very few *in vivo* models for studying the infection prognosis. *S. Typhimurium* infection and colonization in natural resistance-associated macrophage protein-negative (*Nramp1*^{-/-}) C57BL/6 or BALB/c mice induces typhoid fever-like symptoms and helps to unravel the infection biology of *Salmonella* Typhimurium.^{77–79} Since typhoidal serovar and NTS share only 89% of the genes, the findings in *S. Typhimurium* are extrapolated to *S. Typhi*.⁸⁰ However, contradictory reports in the last two decades also indicate that, due to the loss of genes and pseudogenization in *S. Typhi*, all of the findings in *S. Typhimurium* cannot be directly applied to *S. Typhi*. In detail, we have discussed the loss of genes and

pseudogenization in *S. Typhi* in the section on virulence determinants of *Salmonella* pathogenesis. The humanized mouse model in a severely immunodeficient (e.g., SCID or *Rag2*^{-/-}/*γC*^{-/-}) mouse with the human immune system is the nearest animal model to study *S. Typhi* infection. These mice are engrafted with CD34⁺ human umbilical cord blood stem cells, human fetal hematopoietic stem and progenitor cells, or human leukocytes.^{81–84}

More recent research in *Salmonella* biology sheds light on the organoid or enteroid models, which help fill the gap between *in vivo* and *in vitro* research systems. C. A. Nickerson et al. was among the first groups to show a significant difference in *Salmonella* infection in 2D and 3D organoid culture models of Int407.⁸⁵ Two of the broad classifications of the 3D organoid model are mouse-derived and human-derived organoids. Zhang and colleagues performed one of the most primitive works with mouse-derived organoids. The observations revealed the bacteria-mediated tight junction disruption, NF-κB-induced inflammatory response, and downregulation of Lgr5 (stem marker). However, a faulty experimental setup led to infection from the basolateral side.⁸⁶ The intestinal enteroid model also provided an excellent model for studying different cell types regulations such as Paneth cell (PC) degranulation upon LPS interaction and the antimicrobial role of Paneth cell α-defensins.^{87,88}

Human-derived models help to further the studies, as they carry the specific human genetic makeup instead of mouse models. Few *Salmonella* pathogenesis studies utilize adult stem cells (ASCs) and pluripotent stem cells (PSCs) derived from human-enteroid models. In 2018, K. P. Nickerson et al. introduced another human-derived enteroid model system using human tissue biopsies and human ileum. The transcriptional profiling of the bacteria and host tissue revealed that *S. Typhi* downregulated critical host genes that are responsible for bacterial clearance, host immunity, and cytoskeleton rearrangements. The silent phase of infection associated with *S. Typhi* is attributed to the downregulation of SPI-1, which minimizes intestinal inflammation.⁸⁹ Recent studies of *S. Typhi* in the *C. elegans* model system shed light on the usage of this system to answer research questions about *S. Typhi* research.⁹⁰ Enteroid, humanized mouse, and cell culture models will be instrumental in answering the multiple open-ended questions about *Salmonella*.

VIRULENCE DETERMINANTS OF SALMONELLA PATHOGENESIS

Unless otherwise stated, we aim to shed light upon *Salmonella* pathogenesis here, pertaining to typhoidal serovar and NTS. Upon ingestion of contaminated food and water, bacteria enter the digestive tract and overcome the acidic pH of the stomach with an excellent acid tolerance system called *phoPQ*. In the subsequent events, they reach the intestinal milieu, where they further escape several host-innate immune arsenals such as digestive enzymes, bile salts,⁹¹ secretory IgA,^{92,93} antimicrobial peptides (AMPs).^{94–97} *Salmonella* then traverses the intestinal mucus layer to reach the epithelium beneath. In the small intestine, *Salmonella* is taken up preferentially by microfold (M) cells (Figure 2). The M cells are specialized cells that help sample food antigens from the intestinal lumen through pinocytosis. This sampling further channelizes the transfer of *Salmonella* to various immune cells in the Peyer's patches.^{98,99} Alongside *Salmonella* inducing its uptake through bacterial-mediated endocytosis in nonphagocytic cells, *Salmonella*-

mediated endocytosis into the enterocytes is initiated by the adhesion of bacteria to enterocytes by various molecules like fimbrial adhesins. Postadhesion, *Salmonella* can mediate its uptake by inducing membrane ruffling due to extensive modulation of the actin cytoskeleton of enterocytes.

On the other hand, CD18⁺ phagocytes can also phagocytose *Salmonella* from the intestinal lumen, thereby translocating it to Peyer's patches.¹⁰⁰ Once the bacteria reach the reticuloendothelial system, the macrophages can phagocytose the typhoidal serovar and NTS through phagocytosis and macropinocytosis. In the upcoming sections, we discuss the subsequent events about macrophages. The NTS elicits a strong Th1 immune response in immune-competent individuals due to pathogen-associated molecular patterns (PAMPs). It is characterized by IL-18-mediated recruitment of bone marrow-derived phagocytes, neutrophils, and B and T cells in the lamina propria, leading to phagocytosis of invading *Salmonella*. This response limits the dissemination of NTS from becoming a systemic infection, leading to self-limiting gastroenteritis.¹⁰¹

Upon entering the macrophages, *Salmonella* senses the phagosomal environment, activating various virulence arsenals to thrive and replicate in the macrophages in otherwise microbicidal niches and leading to dissemination throughout the reticuloendothelial system.^{102–109} *S. Typhi* can surpass the host immune checkpoints, including lymph nodes that restrict the infection.¹¹⁰ Induction of *Salmonella* pathogenicity island 1 (SPI-1) transcription and Vi-polysaccharide downregulates flagella to subvert the early inflammatory response in *S. Typhi*, one of its well-known PAMPs.^{111,112} In *S. Typhi*, the Vi capsular antigen synthesis begins once the bacterium marks its entry into the ileum region of the gut.¹¹³ *S. Paratyphi A* does not express Vi, yet it is capable of causing typhoid-like illness.²⁵ According to reports, *S. Typhi* lacking the Vi antigen is capable of causing infection,¹¹⁴ indicating that Vi capsular polysaccharide is not entirely indispensable for the pathogenesis of typhoidal serovars.

The molecular mechanisms of *Salmonella* pathogenesis are highly complex and well-coordinated. Pathogenic strains of *Salmonella* spp. differ from their nonpathogenic relatives by harboring specific pathogenicity genes organized into clusters called pathogenicity islands.^{115–117} Pathogenic islands are gene clusters incorporated into the genome, in either the chromosome or a plasmid, with variable GC content and codon usage compared to the surrounding regions. They are also flanked by direct repeats, insertion sequences, or tRNA genes, acting as sites for DNA recombination. Pathogenic strains of *Salmonella* have acquired these islands from other pathogenic bacteria during evolution by horizontal gene transfer. Some are conserved throughout the *Salmonella* genus, whereas others are exclusively found in specific serovars. To date, 24 SPIs have been identified, of which SPI-1 and SPI-2 have been vastly characterized. SPI-1 is required for the bacterium to invade the nonphagocytic epithelial cells, whereas SPI-2 is necessary for bacterial survival and replication inside the macrophages.¹¹⁸ The remaining SPIs contribute to other pathogenic attributes like fimbrial expression, magnesium and iron uptake, multiple antibiotic resistance, intracellular survival, and systemic dissemination.¹¹⁹

S. Typhi is an example of reductive evolution where the serovar has undergone functional inactivation of genes (pseudogenization of 200–300 genes) to adapt specifically to the human host.¹²⁰ *S. Typhi* and *S. Typhimurium* have 11 SPIs

Table 2. Host Factors That Are Exploited by *Salmonella* Effectors to Facilitate Its Uptake into Non-Phagocytic Cells

host complex targeted	bacterial effectors	mechanism	refs
the WAVE regulatory complex (WRC)	SopB, SopE, SptP	the WRC complex is essential for the formation of lamellipodia, which is governed by Rac1 and Arf1 activity. GEF mimic SopE can activate Rac1, and Arf1 is activated by activity of SopB, which helps in the accumulation of PI (3,4,5) P3 and ARNO at the site of entry, leading to the recruitment of WRC and the promotion of the Arp2/3 complex for actin remodelling. SptP is responsible for the inactivation of Rac1 and returning the cell to the resting stage.	267–275
the WASH complex	not identified	the WASH (Wiskott–Aldrich syndrome protein and scar homologue) complex, also responsible for activating Arp 2/3-dependent actin polymerization, acts downstream of RhoA and accumulates at the <i>Salmonella</i> entry site.	270, 276, 277
myosin-mediated contractility	SopB	actin stress fibers are decorated with myosin IIA and IIB upon infection. SopB helps in hijacking and activating myosin II through the activation of RhoA and downstream Rho kinases (Rocks). the exact molecular mechanism remains elusive, but altered phosphoinositide dynamics might be involved.	128, 278
formins	SopB, SopE/E2	formins are a family of proteins that are nucleators of actin polymerization independently of Arp2/3. FHOD1 also lies downstream of RhoA and can be activated by Rac1. SPIRE1 (pathogen entry) and SPIRE2 (replicative niche) are also involved in cytoskeleton remodelling, as these help in nucleating the assembly/bundling of straight actin fiber.	130, 135, 279, 280
the exocyst complex	SipC, SopE/E2	Exo70 is part of a hetero-octameric exocyst complex that helps in vesicle transport, and it interacts with SipC. assembly of an exocyst complex requires activation of RelA by SopE/E2. the exact molecular mechanism for this complex-mediated entry also remains elusive, however, it is proposed that it may fulfill the extra phospholipids requirement during the formation of membrane ruffles.	281
IQGAP1	SopE/E2, SopB	IQGAP1 has a homologous domain of GTPase activating protein (GAP, inactivators of Rho GTPases), thus it binds GTPases (Rac1 and Cdc42) and prevents its inactivation. IQGAP1 also acts as a molecular scaffold for downstream MAPK/ERK signaling and various phosphoinositide kinases that might be in relation to SopB.	282–285
annexins	SopE/E2, SopB	annexins (A1, A2 and A5) are calcium-dependent membrane-binding proteins that indirectly regulate cytoskeleton membrane dynamics, and they accumulate at the site of <i>Salmonella</i> -mediated entry. A2 along with p11 protein binds AHNAK (a phosphoprotein regulator of membrane). exact molecular dynamics have yet to be elucidated.	286
myosin VI	SopE/E2, SopB	myosin VI plays a key role in endocytosis, and SopE specifically recruits it at the site of entry via Rac1-WRC and Rac1-p21activated kinase (PAK) pathway. myosin VI also recruits a PI3P-binding, actin-binding and GEF for Cdc42 called frabin at the site of membrane ruffles.	128, 272, 287–289
villin	SipA, SptP	villin, an actin-binding and severing protein, is required for <i>Salmonella</i> to enter into the polarized enterocytes. it is suggested that severing leads to the generation of barbed ends, which are essential for new filament growth. the activity of villin is regulated by SipA and SptP.	290

in common (1–6, 9, 11, 12, 13, and 16). SPI-8 and SPI-10 were initially found in *S. Typhi* and are considered absent in *S. Typhimurium*. There is only one SPI specific to *S. Typhimurium*, viz, SPI-14, and four SPIs specific to *S. Typhi*, viz., SPI-7, SPI-15, SPI-17, and SPI-18.¹²¹ SPI-19, SPI-20, and SPI-21 are absent in both serovars (*S. Typhi* and *S. Typhimurium*).¹²² SPI-7 and SPI-11 code for the Vi antigen and the typhoid toxin, two specific virulence determinants of *S. Typhi*.¹²³ A type IVB pilus encoded by SPI-7 is usually used by *S. Typhi* while adhering to human monocytes and epithelial cells by interacting with the CFTR receptor.¹²⁰ Other virulence determinants include the flagella, which activate innate immune response via the recognition of monomeric flagellin by the NLR family, apoptosis inhibitory proteins (NAIP), and TLR5 receptors.¹²³

This section discusses how the coordinated expression and functioning of virulence determinants in *Salmonella* aid in its entry, survival, and dissemination in the host body. Research in nonphagocytic cells and *Salmonella* interaction has focused chiefly on *S. Typhimurium*, even in cell culture models. Therefore, in the upcoming section with nonphagocytic cells, most of the work is on *S. Typhimurium* until otherwise stated.

Interaction of *Salmonella* with Nonphagocytic Cells. Much literature suggests that entry into the nonphagocytic cells holds immense importance in disease manifestations, since the primary site of infection resides in the intestinal epithelial cells. Therefore, we have elaborately discussed the current knowledge of the pathogenesis of *S. Typhimurium* in nonphagocytic cells.

SPI-1 Facilitates Entry into Nonphagocytic Cells. In 1989, Galan and Curtiss discovered that the genes responsible for mediating entry into the nonphagocytic cells are encoded by SPI-1.^{124,125} SPI-1 encodes a molecular syringe capable of injecting an array of bacterial effector proteins directly into the

host cells. These effectors modulate host cell signaling (especially inflammatory ones) and induce the uptake of the bacteria into nonphagocytic cells. The general theory is that SPI-1 type 3 secretion system (T3SS) mediated uptake of *Salmonella* into the nonphagocytic host cells occurs through the injection of bacterial effectors, which are responsible for the rearrangement of the cytoskeleton resulting in the formation of membrane ruffles, a process similar to macro-pinocytosis. SopB, SopE, and SopE2 are critical determinants for the uptake of *Salmonella* in epithelial cell uptake, and combined mutation in all three genes shows defects in entry.¹²⁶ SopB is an inositol phosphate phosphatase that acts on phosphatidylinositol species to remove 4'- and 5'-phosphates, which is essential for membrane ruffling.¹²⁷ There is a SopB-dependent increase in phosphatidylinositol-3-phosphate (PI3P), phosphatidylinositol-3,4-bisphosphate (PI(3,4)P2) and phosphatidylinositol-3,4,5-triphosphate (PI(3,4,5)P3) in infected cultured cells and on the SCV membrane.^{128,129} Accumulation of these PIP lipid species leads to the recruitment of several host factors, such as guanine nucleotide exchange factors (GEFs), that further activate an essential Rho GTPase.¹³⁰ SopB also activates Akt or protein kinase B (PKB)-YAP, which facilitates *S. Typhimurium*'s growth inside host cells and inhibits apoptosis.^{131,132} The activity of SopB assisted by Vps34 and Rab5 on a *Salmonella*-containing vacuole (SCV) membrane leads to increased charge on the membrane, leading to lysosomal fusion inhibition conferring protection to SCV from acid hydrolases of the lysosome.¹²⁸ SopB also reduces the overall lysosomal numbers, giving the pathogen an upper hand compared to the host.¹²⁹

On the other hand, *Salmonella* effectors such as SopE2 and SopE mimic host GEFs that activate Rho GTPase Cdc42,¹³³ and SopE can also activate Rac1.^{134,135} Host Rho GTPase is significant in bacterial uptake by nonphagocytic cells such as

enterocytes and epithelial cells in the gallbladder. In conjunction with these effectors, SPI-1-encoded effectors such as SipA and SipC also facilitate uptake by directly interacting with actin-binding proteins. SipC is a part of SPI-1 translocon and can nucleate actin filament polymerization and bundle pre-existing actin.^{136–138} SipA initiates actin nucleation and the bundling activity of SipC by the high-affinity binding and stabilization of actin filaments. Further, SipA also prevents depolymerization by host ADF and cofilin proteins. However, SipA deletion mutants only have reduced invasion capacity, suggesting that SipA is not entirely indispensable but does facilitate the entry of the bacteria.¹⁴¹ In contrast, a recent report challenges the existing model of ruffle-mediated entry into the cells. The report suggests that entry into the mouse gut epithelium occurs through the “discrete-invasion” model. This discrete invasion is facilitated by SipA, which is capable of manifesting significant elongation of local microvilli, and does not favor cooperative invasion.¹⁴² SipB, SipC, and SipD are essential in forming the needle complex. Besides this, they have other functions, e.g., SipB is necessary for *Salmonella*-induced caspase-1-dependent apoptosis and the release of IL-18^{143–145} and SipC interacts with F-actin, which helps in pathogen internalization.¹³⁸ A potential functionality difference might appear between the typhoidal and nontyphoidal serovars due to amino acid substitutions in the SipD translocon of *S. Typhi*.¹⁴⁶ Although these effectors together orchestrate the uptake of the bacteria, several redundant pathways of the host are stealthily exploited by *Salmonella* for its benefit and to gain access to nonphagocytic cells (Table 2).

The invasion may also be influenced by bile, Mg²⁺, and short-chain fatty acids.¹⁴⁷ The liver produces bile continuously and helps in the digestion and absorption of fats. Before its release into the intestines, bile is stored in the gall bladder at high concentrations. It is an essential environmental cue to upregulate virulence gene expression during infection within the host's gastrointestinal tract. *Salmonella* regulates the production of virulence factors following bile exposure. BarA is the sensor kinase that responds to environmental stimuli and acts through its cognate response regulator SirA to induce the expression of invasion genes. This pathway includes the induction of *hilA* expression and a *hilA*-independent effect on *invF* expression.¹⁴⁸ Bile represses the invasion capability of *S. Typhimurium* via BarA/SirA,^{149,150} and *in vitro* studies have shown that bile exposure increased the invasive capability of *S. Typhi* in HeLa cells. A protein stability assay reveals that this observation is attributed to the more excellent stability of one of the chief regulators of SPI-1, HilD, upon bile exposure in *S. Typhi*.¹⁵¹

The temperature differentially regulates the expression of T3SS in typhoidal and nontyphoidal serovars. During fever, an increase in body temperature (39–42 °C) in an infected host reduces the invasion and motility in typhoidal serovars. SPI-2 also has a temperature-dependent regulation. Higher temperatures (42 °C) increased SPI-2 expression in both *S. Paratyphi A* and *S. Typhimurium*, although a significant increase in SPI-2-mediated intracellular replication was found only in *S. Paratyphi A*.¹⁵² This is another example of adaptation, since fever marks the beginning of systemic dissemination of typhoidal serovars, where intracellular survival is more important than invasion.¹²⁵

The Dual Lifestyle of *Salmonella* in Nonphagocytic Cells. After entering the epithelial cells, the pathogen can lead a dual lifestyle, either cytosolic or vacuolar. *Salmonella* remains

encapsulated within a host membrane compartment, SCV, or it might quit the vacuole to thrive in the host cytosol. *Salmonella* modulates the intricate pathways of host endosomal–lysosomal maturation with SPI-2 effectors to establish a successful replicative niche. Once inside the cell, there is the downregulation of the expression of SPI-1 and the upregulation of another molecular syringe SPI-2-encoded T3SS, which spans the vacuolar membrane and bacterial membrane and can inject several effectors from the bacterial cytosol to the host cytosol. The central cues for the induction of SPI-2 are limited nutrients, low pH, antimicrobial peptide accumulation in the vacuolar lumen, and decreased Mg²⁺ concentration.¹⁵³ The pH sensing mechanism by intracellular *Salmonella* is mediated by a protein complex comprising SsaM, SpiC, and SsaL encoded by SPI-2. This complex can sense low and neutral pH and regulate effector translocation.¹⁵⁴

A recent review on the genetic tuning of *S. enterica* describes all the aspects involving genetic switches of *Salmonella* to thrive in hostile host niches.¹⁵⁵ SPI-2 injects as many as 43 different effector proteins into the host cytoplasm, assisting in SCV maturation and establishing a replicative niche.^{156–158} The SCV maturation is comprised of three different stages: early (<30 min postinfection), intermediate (30 min to 5 h postinfection), and late (>5 h postinfection). Each stage is distinct regarding bacterial and host proteins recruited on SCVs. Apart from mediating entry, SopB also serves a highly vital role in the initial biogenesis of SCV: it alters the phosphoinositide dynamics of the SCV membrane through hydrolysis of PI(3,5)P2 and PI(3,4,5)P3 to PI(3)P.^{159–161} It is also responsible for recruiting GTPases, Rab5, and PI(3) kinase Vps34, which induces rapid remodelling of the membrane through early endosome antigen 1 (EEA1) mediated fusions with early endosomes within as little as 5 min of entry.^{128,160,162} Recently, it was reported that SopB triggers rapid recruitment of cytosolic sorting nexin 18 (SNX18; an SH3-PX-BAR domain sorting nexin protein) that further assists SopB in its phosphoinositide phosphatase activity.¹⁶³ Next, the SCV membrane acquires several endocytic host protein markers, such as transferrin receptors (TfR), Rab4, and Rab11,^{164,165} which act as protective shelters in an otherwise hostile host environment.

Salmonella-Containing Vacuole (SCV) Maturation and Replication. The SCV maturation mimics host endocytic pathways by shedding off early, sorting, and recycling membrane markers within 30 min postinfection and acquiring a set of late endocytic marker proteins such as vacuolar-ATPase, Rab7, Rab9, lysosomal glycoproteins (LAMP1, LAMP2, and LAMP3/CD63), and RILP (Rab-interacting lysosomal protein).^{166–170} Rab7 is the primary small GTPase acting in late endosomal and lysosomal vesicles, and Rab7 facilitates the recruitment of lysosomal glycoproteins, RILP, FYVE (another Rab-interacting lysosomal protein), and coiled-coil domain-containing protein 1 (FYCO-1).^{171–173} Rab7 and its effector RILP recruit the motor protein dynein to SCV to initiate its centripetal movement, resulting in peri-Golgi localization of SCV. However, it is very compelling that *Salmonella* selectively excludes a few late endocytic markers such as mannose-6-phosphate receptors (M6PR), lysobisphosphatidic acid (LBPA), and lysosomal hydrolases (cathepsins)^{166,167,174,175} from the SCV membrane in the process of SCV maturation.

S. enterica forms a highly complex stabilized network of tubules called *Salmonella*-induced tubules (SITs). Some of the

Table 3. *Salmonella* Pathogenicity Islands (SPIs), Genomic Structure, and Functions in *S. Typhi*

SPI	effectors	known function	refs
SPI-3 (17-kb pathogenicity island located at 82 min, just behind the <i>selC</i> tRNA locus of <i>Salmonella</i>)	in the <i>mgfCB</i> operon, the gene <i>mgfC</i> is specific for <i>Salmonella</i> . <i>mgfB</i> which is a Mg ²⁺ -transporting ATPase. Another Mg ²⁺ transporter coded by SPI-3 is <i>mgfA</i> . SPI-3. It also harbors the <i>marT-fidL</i> operon, encoding MarT transcriptional regulator and a hypothetical protein FidL.	in the <i>mgfCB</i> operon, the gene <i>mgfC</i> is specific for <i>Salmonella</i> , facilitates intramacrophage survival in growth in low Mg ²⁺ media, and survival in acidic environments of endosomes resulting from SPI-1-mediated invasion. <i>MisL</i> , coded by SPI-3, is an extracellular matrix adhesin involved in intestinal colonization	the region adjacent to the <i>sec</i> tRNA region hosts the maximum amount of variations between <i>S. Typhi</i> and <i>S. Typhimurium</i> along with some pseudogenes like STY4024 (<i>cigR</i>), STY4027 (<i>marT</i>), STY4030 (<i>nisL</i>), STY4034, STY4035, and STY4057. A few more pseudogenes are also noted in other regions of SPI-3 like STY4012, STY4007, and STY4003. In brief, <i>MisL</i> , its regulator MarT, and an unknown putative transcriptional regulator (STY4012) are inactivated in <i>S. Typhi</i> . expression of <i>S. Typhimurium marT-fidL</i> in <i>S. Typhi</i> negatively affected the survival of the bacterium inside macrophage cells but not epithelial cells
SPI-4 (24 kb fragment located next to a potential tRNA-like gene at centisome 92)	SPI-4 encodes a type I secretion system (<i>sisCDF</i>), which encodes the almost 600 kDa protein (encoded by <i>SiiE</i>)	<i>SiiE</i> is a nonfimbrial adhesin protein, 600 kDa in size, containing 53 repeats of Ig domains. <i>SiiE</i> is secreted into the culture medium and mediates contact-dependent adhesion to the epithelial cell surface	SPI-4 has role in the intracellular uptake and survival in macrophages for <i>S. Typhi</i> . <i>SiiE</i> is coded by only one ORF in <i>S. Typhimurium</i> (STM4261), unlike in <i>S. Typhi</i> , where it is segmented into two ORFs in <i>S. Typhi</i> (STY4458 and STY4459) due to the presence of a stop codon. this implies that <i>siiE</i> is a pseudogene in <i>S. Typhimurium</i> that correlates with the loss of function of adhesin responsible for intestinal colonization by <i>S. Typhimurium</i>
SPI-5 (approximately 7.6 kb long and has been found next to <i>serT</i> tRNA)	encodes the effector proteins for both the T3SS system of SPI-1 and SPI-2	SopB translocated by SPI-1 T3SS helps in membrane ruffling and invasion. PipA contributes in the development of systemic infection. PipB translocated by SPI-2-encoded T3SS facilitates accumulation of lipid rafts and helps in intramacrophage survival	SPI-5 has been observed between the two serovars apart from an additional ORF (STY114) that putatively encodes a transposase in <i>S. Typhi</i>
SPI-6 (located next to <i>aspV</i> tRNA gene at centisome 47, and it extends for 47 kb and 59 kb in both <i>S. Typhi</i> and <i>S. Typhimurium</i>)	SPI-6 has the <i>saf</i> gene and the <i>pagN</i> gene	the <i>saf</i> gene codes for fimbriae and the <i>pagN</i> gene codes for the invasion protein in both the serovars	a fragment 10 kb in size is present downstream of the <i>saf</i> operon only in <i>S. Typhi</i> , which includes putative transposase remnants (STY0343 and STY0344, both of which are pseudogenes), the fimbrial operon <i>tfABCDF</i> , and genes <i>tinR</i> (STY0349) and <i>fioA</i> (STY0350). although the T6SS gene cluster is intact in <i>S. Typhi</i> , the protein complex is thought to be nonfunctional due to the presence of a pseudogene form of <i>Scil</i> (VipB homologue). Wang et al. have disproved this assumption and have identified the genes <i>scfA</i> , <i>scfG</i> , <i>scfS</i> , and <i>vrgS</i> as important for T6SS function
SPI-7 (largest SPI, 133 kb, located between two partially duplicated copies of the tRNA- <i>pheU</i> gene and contains about 150 genes)	encodes the capsular polysaccharides or the Vi antigen. it contains the <i>pil</i> gene cluster along with some of the genes of the conjugative plasmid like <i>tra</i> and <i>sam</i>	the <i>pil</i> gene cluster that is responsible for coding many virulence factors along with the SopE prophage (STY44) that encodes the SPI-1 effector SopE	the Vi capsule also acts to inhibit flagellin expression, causes limited recognition of <i>Salmonella</i> by NAIP, and helps to reduce levels of pyroptosis and IL-1 β secretion of macrophages. Along with this, Vi has been reported to bind to cell surface, thus dampening the inflammation caused by MAPK signaling or IL-8 production
SPI-8 (6.8 kb and has been next to <i>pheV</i> tRNA gene that is found next to SPI-13)	encodes for <i>pheV</i>	the exact function of SPI-8 is yet to be elucidated but it is known to code for putative virulence factors	120, 304, 305
SPI-9	encodes for virulence factors of the type I secretion system and encodes RTX-like protein. It shares a 40% nucleotide homology to <i>siiCDEF</i> genes from SPI-4	arranged in an operon whose promoter was upregulated in low pH and high osmolarity conditions in a Rpos-dependent fashion. All the proteins encoded by this pathogenicity island localize in the membrane fraction, supporting their putative role as TISS. SPI-9 contributed to the adherence of <i>S. Typhi</i> to epithelial cells under high osmolarity or low pH or in situation mimicking conditions of the small intestine	80, 298, 305
SPI-10 (32.8 kb, next to <i>lenX</i> tRNA gene at centisome 93)	In <i>S. Typhimurium</i> , it is substituted by a 20 kb uncharacterized island without any SPI annotation that comprises functionally unrelated genes sharing little homology to sequences from the genomic database	there is possible relationship of this sequence with DNA repair, deletion of this island in <i>S. Typhimurium</i> 14028 attenuated the virulence of the strain	304, 306, 307
SPI-11 (6.7 kb in <i>S. Typhimurium</i> and 10 kb in <i>S. Typhi</i>)	encodes for virulence factors of the type I secretion system and encodes RTX-like protein. It shares a 40% nucleotide homology to <i>siiCDEF</i> genes from SPI-4	a full P4-related phage named ST46 that harbors <i>p77Z</i> as cargo genes responsible for encoding the Ser-Thr protein involved in <i>S. Typhi</i> survival in macrophages, many other pseudogenes are also found in <i>S. Typhi</i> , namely, STY4835 (IS1230), STY4836 (<i>sefA</i>), STY4839 (<i>sefD</i>), STY4841 (<i>sefR</i>), STY4845 (a thiol-disulfide interchange protein), and STY4848 (putative transposase), the homologous ORFs STY4842–4846 of <i>S. Typhi</i> includes the <i>sgA</i> gene. The <i>sgA</i> gene encodes a functional disulfide oxidoreductase in <i>S. Typhimurium</i> unlike that in <i>S. Typhi</i> , where it is a pseudogene (STY4845). It contributes to virulence factors that lead to the formation of <i>Set</i> fimbriae, a phenomenon restricted to <i>S. Typhi</i> and <i>S. Enteritidis</i> . The role of <i>Cryptic bacteriophage</i> is yet to be elucidated	308
SPI-12 (is located next to <i>proL</i> tRNA centisome 48, 6.3 kb long in <i>S. Typhi</i>)	SPI-12 is responsible for causing systemic infection in mice for <i>S. Typhimurium</i> 14028	in <i>S. Typhi</i> , three ORFs are pseudogenes, viz., STY2466, STY2468, and STY2469. Only the <i>sspH2</i> gene is functional in this island including the typhoid toxin CdtB, the CdtB toxin is elaborated in the section Interaction of Salmonella Typhi with Phagocytes	146, 309

Table 3. continued

SPI	effectors	known function	refs
SPI-13 (next to the <i>pheV</i> tRNA gene at centromere)	In <i>S. Typhimurium</i> , the ORFs STM3117-3123 code for virulence-associated genes	the genes are involved in intracellular replication in murine macrophages and contribute to systemic infection of mice	<i>S. Typhi</i> SPI-8 harbors two bacteriocin immunity proteins (STY3281 and STY3283) and four pseudogenes. The virulence properties of SPI-8 are unknown. The conserved 17 kb in SPI-13 has not been found to contribute to virulence
SPI-14		the function of this SPI has yet to be understood	although these are found in <i>S. Enteritidis</i> and <i>S. Typhimurium</i> , they are absent from <i>S. Typhi</i> and <i>S. Paratyphi A</i>
SPI-15 (6.5 kb island that is present near the <i>glyU</i> tRNA gene in <i>S. Typhi</i>)	absent in <i>S. Typhimurium</i>	constitutes five islands encoding hypothetical proteins, which have been identified by bioinformatic analysis	³⁰⁴ ³¹²
SPI-16 (4.5 kb fragment located next to <i>argU</i> tRNA)	five ORFs in <i>S. Typhimurium</i>	seven ORFs in <i>S. Typhi</i> . Four of these genes are pseudogenes in <i>S. Typhi</i> , the three remaining ORFs in <i>S. Typhi</i> have a high level of similarity with P22 phage involved in seroconversion. They are suggested to cause O-antigen glycosylation and cell surface variation.	³¹² , ³¹³
SPI-17 (inserted next to an <i>argW</i> tRNA site)	this pathogenicity island contains seroconversion genes homologous to P22 phage	it showed a high similarity to genes of SPI-16, including a putative lipopolysaccharide modification acyltransferase	³¹²
SPI-18	This genomic island is missing in <i>S. Typhimurium</i>	codes for two putative genes. One of these is <i>hlyE</i> , encoding a hemolysin related to the <i>Escherichia coli</i> K12 HlyE hemolysin. Fuentes et al. have shown that <i>S. Typhi</i> <i>hlyE</i> mutants are impaired in their capability to invade human epithelial cells in vitro, and its heterologous expression in <i>S. Typhimurium</i> has been seen to improve the colonization of deep organs in mice. Additionally, a secreted 27 kDa invasin, coded by <i>taiA</i> (STY1499), increases bacterial uptake by human macrophages	³⁰⁴ , ³¹⁴ , ³¹⁵

well-studied SITs are *Salmonella*-induced filaments (SIFs). SIF formation occurs mainly in epithelial cells, and SIFs are the only SITs harboring LAMPs. *Salmonella*-induced filament A (SifA) is responsible for forming SIFs, and the SifA mutant cannot induce SIFs. The host protein that interacts with the SPI2 effector SifA is the SifA- and kinesin-interacting protein (SKIP, aka PLEKHM2). The association of SifA-Skip inhibits the recruitment of M6PR by sequestering Rab9, which is essential for the maturation of endocytic vesicles. The reduced M6PR onto the SCV membrane leads to reduced delivery of lysosomal enzymes inside the SCV, thereby conferring protection from various host degradative enzymes.¹⁷⁶ SopD2, another SPI-2 effector, disrupts the Rab7-mediated recruitment of RILP and FYCO1 at the late stage of SCV maturation, leading to the shedding of RILP and FYCO1.^{172,173,177} SseF and SseG form a tethering complex along with the Golgi-associated protein ACBD3.^{178,179} SIFs also have access to the host cell's endocytosed content,^{180–182} suggesting that SIFs enable nutrient acquisition. Long filamentous structures are potent in providing larger surface areas for more nutrient uptake and promoting bacterial survival and, more importantly, replication along with SCV. A recent study by Hensel and colleagues demonstrated a continuum between the SIFs and SCVs.¹⁸³ Moreover, auxotrophic mutants, incapable of inducing SIFs, cannot access the host nutrients.¹⁸⁴ There is a dearth of research on the exact molecular mechanism of *Salmonella* replication inside the host cellular niche. However, *Salmonella* perturbs the SCV and the lysosome ratio to successfully thrive inside the host niche by replicating with the SCV to maintain one bacterium per vacuole. The requirement of a dedicated vacuolar compartment per bacterium in the host cell increases the vacuolar load. Simultaneously, the SCV remains nonbulky, which helps avoid lysosomal fusion.¹⁸⁵ About 10–20% of intracellular bacteria quit their vacuolar niche to enter the cytosol.^{186–188} About half of the SCVs are essential targets for host xenophagy and are subsequently eliminated, and the other half escape this by hyperreplication.^{179,189} The cytosolic bacterial population triggers host cell pyroptosis and extrusion of enterocytes from the intestinal lumen by inducing a local burst. The cytosolic lifestyle gives *Salmonella* an advantage over the host, as hyperreplication in the enterocytes causes localized inflammation, and the bacteria can silently replicate in the vacuolar niche and remain hidden from host immune arsenals.

Salmonella Modulates Host Endocytic Protein. Apart from these host factors, another set of host proteins plays a role in SCV maturation and biogenesis, called soluble N-ethyl-maleimide-sensitive factor attachment receptor (SNARE) proteins. SNAREs are the proteins that help endocytic vesicular fusion and fission and serve an intricate function in maintaining host endolysosomal pathway homeostasis. Newer insights into the role of SNAREs in SCV biogenesis suggest that *Salmonella* also modulates the host endolysosomal pathways to facilitate its survival and replicative niche. A recent report suggests that a host SNARE called syntaxin 8 interacts with SipA (SipA mimics cognate SNARE of syntaxin 8) to promote its fusion to early endosomes, thereby recruiting other syntaxins such as syntaxin 7 and syntaxin 13 to the SCV membrane, which potentially arrest its maturation and further assist in survival.¹⁹⁰ The SCV and infection-associated macropinosomes (IAMS) fuse with the help of SNARE proteins (SNAP25 and STX4) to maintain dynamic SCV growth and shrinkage.¹⁹¹ SPI-2 mediates the SCV division in a syntaxin 3-

dependent manner to facilitate *Salmonella* survival.¹⁹² SipC recruits syntaxin 6, which helps acquire LAMP1 on SCV from the Golgi apparatus.¹⁹³ *Salmonella* can partially trigger autophagy in epithelial cells via SPI-1-encoded T3SS-1-mediated damage to the SCV membrane, exposing the SCV lumen to various host cytoplasmic ubiquitin ligases. Apart from this, the damaged SCV can also be recognized by galectin 8, which is capable of recruiting autophagic machinery.¹⁹⁴ SCV damage also leads to the release of *Salmonella* in the cytosol, which the ubiquitin systems of host cells can identify. Subsequently, cytosolic *Salmonella* leads to the bacteria's polyubiquitination, which is recognized by NDP52, OPTN, and p62 adaptor molecules linked to LC3B autophagic capture.¹⁷¹ In Figure 3, we have described the necessary steps involved in SCV biogenesis, maturation, and interaction with host–endosomal–lysosomal pathways. However, it is interesting that if the SCV membrane remains undamaged, *Salmonella* can subvert the host autophagic machinery and thrive inside the host macrophages by employing SopB-mediated mechanisms.¹⁹⁵

Interaction of *Salmonella* with Phagocytes. The phagocytes engulf *Salmonella* by a process called phagocytosis and initiate killing by mounting an antimicrobial response in the form of reactive oxygen species (ROS), reactive nitrogen species (RNS), cationic antimicrobial peptides (CAMPs), metal ion starvation, and acid stress.¹⁹⁶ Professional antigen-presenting cells such as dendritic cells and macrophages can prime CD4⁺/CD8⁺ T lymphocytes by presenting bacterial antigens via major histocompatibility complexes (MHC) I and II. IL-18 influences the activation of CD4⁺ T lymphocytes, resulting in the secretion of IFN- γ and the clearance of *S. Typhimurium* infection from the spleen of mice in a MHC-II-independent manner.¹⁹⁷ CD8⁺ T lymphocytes are essential in clearing the infection caused by cytosolic bacteria such as *Listeria monocytogenes*.^{198,199} However, the same is unknown during the infection of vacuolar pathogens such as *S. Typhimurium*.^{200,201} The successful onset of typhoid fever in humans by *S. Typhi* depends on its ability to evade and eventually establish an intracellular proliferating niche in phagocytes. In the following part of this Review, we discuss the intelligent approaches employed by *S. Typhi* and *S. Typhimurium* to deceive the immune system and initiate systemic infections in humans and mice.

Intracellular Life of *Salmonella* in the Macrophage. The virulence of *S. Typhi* is unique in comparison with that of *S. Typhimurium*, which is capable of thriving inside a wide range of host cells, including murine macrophages (RAW264.7 and J774A.1 cells), human monocyte-derived macrophages (THP-1 and U937 cells),^{202–204} dendritic cells,^{205,206} and B lymphocytes.^{207–209} To escape the immune response, invasive strains of *Salmonella*, such as *S. Typhi* Ty2 and *S. Typhimurium* D23580, downregulate their metabolic activity and start consuming lipids over carbohydrates.²¹⁰ After entering macrophages, *S. Typhimurium* stays inside modified membrane-bound SCVs.^{211,212} The mature SCV recruits several proteins like LAMP-1 and Rab7 and inhibits their fusion with the lysosome, similar to nonphagocytic cells.^{185,211,212} The presence of the SCV membrane protects the bacteria from intracellular threats such as ROS, RNS, CAMPs, etc.^{213,214} Unlike the nontyphoidal serovars, *S. Typhi* prefers to invade and survive only inside human monocyte-derived macrophages.^{215,216}

Table 4. Extra-Intestinal Infections by *S. Typhi*

organ infected	complications	symptoms	pre-disposing factors	diagnosis	treatment	refs
brain	"typhoid encephalopathy" under severe conditions, Parkinson's syndrome, motor-neuron disease, transient amnesia, symmetrical sensory-motor neuropathy, schizophrenia, psychosis, and Guillain-Barre syndrome	altered consciousness, delirium, and confusion along with other rare neurological symptoms like myelitis, altered sleep pattern, meningitis, and acute psychosis		neuroimaging with magnetic resonance imaging (MRI), angiography, computed tomography (CT), and/or radionuclide scans might be handy for diagnosis of brain abscesses, epidural empyemas, and subdural empyemas		316–317;318;319
cardiac impairments	major complications like (i) myocarditis and (ii) endocarditis to pericarditis and arteritis as rare complications	(i) microcirculatory disturbances, edema, inflammation of the heart intramural vessels, lymphocytic, and macrophage infiltration of the stroma, sometimes with the formation of granulomas, and dystrophic and necrotic changes	underlying cardiac complexities like heart valvular abnormalities, congenital heart disease, or rheumatic heart disease	(i) abnormal doppler signal, ECG, CMR, indicators of cardiac injury (CK, AST, and LDH), electro-myocardial biopsy (EMB). (ii) culturing the pathogen from the blood, transthoracic or transesophageal echocardiography might reveal the presence of vegetation	antibiotics and supportive management.	320, 321
lung disease	bronchopneumonia, lobar pneumonia, pleurisy with effusion, and empyema	fever, chills, coughs (with or without sputum), pleuritic pain, coarse crackles and bronchial breathing on auscultation, diarrhea, and leukopenia	prior abnormalities of lung or pleura with the presence of lung malignancies in some cases. mortality is usually high in geriatric patients, with underlying malignancies and immunosuppression due to antineoplastic treatments	chest radiographs or by isolation of the bacterium from sputum, protected specimen brush (PSB) material of bronchial secretions	<i>Salmonella</i> pneumonia calls for at least 2 weeks of antimicrobial therapy, under unresponsive antibiotic therapy, lobectomy might be an option	322–324
liver	hepatitis	high fever, relative bradycardia, and left shift of WBCs		liver damage markers like elevated serum alanine and aspartate transaminase levels, alkaline phosphatase levels, and γ -glutamyl transferase levels, abdominal ultrasound, Widal test, stool culture, and blood culture		325
spleen		fever, chills, tenderness in the left upper quadrant, and splenomegaly	hemoglobinopathies, impaired host resistance, subacute bacterial endocarditis, IV drug abuse, trauma, diabetes mellitus, skin sepsis, respiratory tract infections, immunodeficiency, and urinary tract infections	ultrasonography (USG), USG-guided aspiration followed by culturing the pathogen, Widal test, stool culture, and blood culture	drainage of the largest abscesses along with antibiotic regimen is the favorable treatment, percutaneous drainage preferred. Patients with multiple abscesses unresponsive to percutaneous drainage might call for a splenectomy	326, 327
urinary tract			structural or functional abnormalities, pyelonephritis, dermoid cyst, calculi, dermoid cyst, and renal transplant		needs the proper antimicrobial regime, in the case of a perinephric abscess, a drainage procedure might also be required in addition to the administration of antibiotics	328
genital tract			abscesses in kidney and nephrons, rare complications are IgA nephropathy, hemolytic-uremic syndrome, acute tubular necrosis, and Henoch-Schönlein purpura		7–14 days of antibiotic treatment in the case of genito-perinephric abscess, a drainage procedure might also be required if underlying complications as stone or abscess collection are seen	329, 330

organ infected	complications	symptoms	pre-disposing factors	diagnosis	treatment	refs
musculoskeletal system	(i) osteomyelitis and (ii) septic arthritis	(i) Typically, an infection of the long bones like femur and humerus; it might also affect the lumbar vertebrae, tibia, radius, and ulna. (ii) the chondroosternal junctions, the hip, the sacroiliac joints, the spine, and the knee	(i) predilection for patients with systemic lupus erythematosus (SLE), diabetes mellitus, lymphoma, liver and cardiovascular diseases, previous surgery or trauma, and patients on steroids. (ii) immunosuppressed individuals or children with congenital diseases where bacteremia has the propensity to spread via hematogenous route to larger joints	<i>Salmonella</i> osteomyelitis can be confirmed by simultaneous isolation of <i>Salmonella</i> sp. from blood and pus of affected musculoskeletal site, MRI, CT, and radiographs	antimicrobial therapy and surgical debridement	331
skin	Rose spots	red, blanchable macular lesions 2–4 mm in diameter, which show up in 50% of the cases of enteric fever, within the seventh to twelfth day from the onset of symptoms; rose-spots are seen to occur in crops of 5–10 lesions on the lower chest and upper abdomen and may last for 3–4 days		<i>Salmonella</i> can be cultured from the puncture biopsies	cured with antibiotics alone without surgical intervention	15

Table 4. continued

Host Restriction of *S. Typhi* during Macrophage Infection. The inability of *S. Typhi* to thrive inside murine macrophages can be attributed to the absence of virulent gene *gtgE* that codes for a cysteine protease GtgE which is secreted into the host cell cytosol by SPI-2 T3SS.^{217,218} Additionally, *S. Typhi* cannot produce the GTPase-activating protein SopD2 due to pseudogenization.²¹⁹ While staying in murine macrophages, *S. Typhimurium* employs functionally active GtgE and SopD2 to inhibit the recruitment of Rab29, Rab32, and Rab38 GTPases on the SCV membrane.^{219,220} Rab29, Rab32, and Rab38 and their cognate guanine nucleotide exchange factors BLOC1, BLOC2, and BLOC3 are associated with the transportation of melanin-synthesizing enzymes and their phenyl oxidase intermediates with potential antimicrobial activities into lysosome-like organelle called melanosomes.^{219,221} In murine macrophage and dendritic cells, the Rab32–BLOC3 pathway helps deliver itaconate, a metabolite that has higher antimicrobial activity and is produced in mitochondria from aconitate decarboxylase, into SCV to restrict the intracellular growth of *S. Typhi*.²²² The pseudogenes in the *S. Typhi* genome facilitate bacterial evolution and enhance their survival fitness inside a human host.

Role of *Salmonella* Pathogenicity Islands of *S. Typhi* in Intramacrophage Survival. Contrary to SPI-1 of *S. Typhi*, SPI-2-encoded T3SS and antimicrobial resistance genes showed markedly increased expression. Unlike nontyphoidal serovars, *S. Typhi* can activate the inflammasome in monocyte-derived macrophages two hours postinfection in a SPI-1-dependent manner.²²³ As an early response to *Salmonella* sp. infection in macrophages, the antibacterial oxidative burst is induced by NADPH phagocytic oxidase, followed by the activation of inducible nitric oxide synthase (iNOS), which creates a prolonged bacteriostatic nitrosative burst.¹⁹⁶ Interestingly, macrophage-resident *S. Typhimurium* impairs the NADPH phagocytic oxidase-dependent respiratory burst in an SPI-2-dependent manner.^{104,224}

On the contrary, *S. Typhi* infection in human monocyte-derived macrophage cells is independent of SPI-2-encoded translocon protein SseB and basal secretion apparatus SsaR.²²⁵ Using the transposon-directed insertion site sequencing (TraDIS) technique, Karlinsey et al. proved that SPI-2-encoded T3SS of *S. Typhi* is dispensable for the induction of systemic typhoid fever in the humanized mouse model.²²⁶ Expression of the functionally active protein of the *S. Typhimurium*-encoded *marT-fidL* operon in *S. Typhi* (where the same gene is present in the form of a nonfunctional pseudogene) enhanced its susceptibility toward *in vitro* peroxide stress by suppressing the expression of *surV* and aggravated its killing in human monocyte-derived macrophages.²²⁷ The type IVB pili encoded by the *pil* operon located in SPI-7 of *S. Typhi* is responsible for augmenting the expression of NF-κB and proinflammatory cytokine IL-6 in THP-1 cells in a protein kinase C-dependent manner.²²⁸ The inhibition of type IVB pili of *S. Typhi* using a high-affinity single-stranded RNA aptamer (S-PS_{8,4}) impaired bacterial entry in THP-1 cells, implicating an essential role of pili in mediating bacterial interaction with the host macrophage.²²⁹

Role of Typhoid Toxin in Intramacrophage Survival of *S. Typhi*. The SPI-11 of *S. Typhi* expresses an A₂B₅-type typhoid toxin. It is a multimeric protein complex having catalytically active CdtB (with DNaseI activity) and PltA (with ADP ribosyl transferase activity) domains and five PltB

Salmonella and Host endocytic pathway




Figure 3. *Salmonella*-containing vacuole (SCV) biogenesis, maturation, and interaction with host endolysosomal pathways.

monomers that constitute the base of the toxin.^{123,230} The low Mg²⁺ ion concentration of SCV triggers the PhoPQ two-component system, which activates the *cdtB*, *pltA*, and *pltB* operons encoding the structural and functional subunits of the typhoid toxin and suppresses the expression of histone-like protein H-NS.²³¹ Deleting the *phoP* gene from *S. Typhi* attenuated its intracellular survival in epithelial and macrophage cells.²¹⁵ Upon secretion of the typhoid toxin from the lumen of SCV, it is transported to the cell membrane with the help of Rab29.²³² After being secreted from the infected cells, it intoxicates the surrounding target cells in an autocrine or paracrine fashion and increases the severity of typhoid fever.²³⁰ The typhoid toxin induces DNA damage in THP-1 cells, eventually resulting in the exhaustion of RPA, a sensor of ssDNA/DNA replication, and the formation of γH2AX foci, which brings senescence. The mechanism behind the

replication and senescence has yet to be understood; however, it could be a reason for the higher spread of *S. Typhi* infection.²³³ Williams et al. proved that the expression of the CdtB toxin in the nontyphoidal serovar of *Salmonella* sp. *Salmonella Javiana* induces autophagy and cell death in infected macrophages.²³⁴ However, despite the high amino acid sequence similarity between Javiana and Typhoid toxins, there is a difference in the evolutionary host tissue adaptation and cell tropism of both the organisms.²³⁵

Role of Other Virulent Genes of *S. Typhi* in Intramacrophage Survival. A plethora of virulent genes assist in the survival of *S. Typhi* in macrophages. The global gene expression profile of *S. Typhi* showed that it could also express both SPI-1- and SPI-2-encoded type III secretion systems and virulence factors (SPI-1, *prg*, *sip*, *spa*, and *inv*; SPI-2, *pipB* and *sifB*) during infection and survival within

macrophages. In addition, *Salmonella* Typhi can upregulate the expression of several virulence determinants (two-component systems and regulators), such as *phoPQ*, *ssrAB*, and *slyA*, while infecting macrophages.²³⁶ Transposon mutagenesis revealed that mutation in *ssaQ*, *ssaP*, and *ssaN* impaired the intracellular survival of *Salmonella* Typhi in macrophages.²³⁷ In contrast, the uninterrupted intracellular growth of SPI-2-deficient *S. Typhi* showed that neither *PhoPQ* nor SPI-2 was required for infection in THP-1 cells.^{226 225}

The alternative σ -factor *rpoS* that regulates the expression of *spv* (*Salmonella* plasmid virulence) during the systemic infection of *S. Typhimurium* plays a vital role in the virulence of *S. Typhi*. Deleting *rpoS* from the *S. Typhi* genome makes the bacteria susceptible to NO-dependent host defense even inside both murine (RAW264.7) macrophages.²³⁸ Wang et al. reported that deleting *sufC* enhances *Salmonella* Typhi's susceptibility toward oxidative stress and reduces its survival inside the macrophages.²³⁹ The virulence-associated capsular polysaccharide (Vi antigen) of *S. Typhi* plays a diverse role in its survival inside phagocytes. It can abolish the nitric oxide- and reactive oxygen species-dependent innate immune response in monocyte-derived macrophage cells and neutrophils.²⁴⁰ In *S. Typhi*, the expression of the Vi capsular antigen is positively regulated by OxyR, which eventually induces hydrogen peroxide inducible genes.^{241,242} Further, the Vi capsular antigen results in reduced binding of complement component 3 (C3) on the surface of *S. Typhi*, thus rendering protection against complement-mediated phagocytosis and preventing its clearance from the liver, spleen, and blood of mice.²⁴³ The Vi antigen-dependent abrogation of IL-8 expression in infected THP-1 cells is the reason behind the deficiency of neutrophils in intestinal infiltrates of patients suffering from typhoid fever.²⁴⁴ Due to the presence of the Vi capsular antigen around its surface, *S. Typhi* can restrict the recruitment of complement component 5a (C5a) and thus inhibit the C5aR-dependent chemotactic movement of neutrophils.²⁴⁵ *S. Typhi* fimbriae also regulate phagocytosis and intracellular survival in THP-1 cells.²⁴⁶ *S. Paratyphi A* uses the O2 antigen to prevent the binding of immunoglobulin IgM and thus inhibit the respiratory burst in primary murine and human neutrophils.²⁴⁷

Karinsey and colleagues showed the importance of iron acquisition and utilization during *in vivo* infection caused by *S. Typhi*, where the *iroCDEN* mutant could not induce typhoid fever in hu-SRC-SCID mice.²²⁶ While infecting THP-1 macrophages, wild-type *S. Typhi* secretes eukaryote-like serine-threonine kinase from SCV into the host cytoplasm, which phosphorylates myelin basic proteins (MBPs) and eventually enhances the expression of proinflammatory cytokines like TNF- α and IL-6.²⁴⁸ The bacterial noncoding RNA (ncRNAs) *malS* are crucial in regulating *S. Typhi* virulence inside the macrophage. The intramacrophage life of *S. Typhi* was notably hampered by the overexpression of 5' UTR of *malS* (*malS*-5'UTR), which downregulated the expression of *mgtC* that maintains ATP homeostasis in the bacteria.²⁴⁹ A study conducted by He et al. implicated that pR_{ST98}, a hybrid resistance-virulence plasmid of *S. Typhi*, is responsible for suppressing autophagy and promoting the survival of the bacteria in infected macrophages.²⁵⁰ Recent studies demonstrated that nontyphoidal *Salmonella* serovars widely use numerous novel virulence factors, such as outer membrane proteins (OmpA and PgtE), YdcP, and a novel putative collagenase, to interact with host macrophages.^{251–254}

High sequential homology for these novel virulence factors between *Salmonella* Typhi and Typhimurium indicated their involvement during typhoid fever. However, thorough and detailed research is required to annotate their exact functions in *S. Typhi*.

S. Typhi Infection in Dendritic Cells. During chronic *Salmonella* infection, the greater abundance of macrophages, neutrophils, and dendritic cells in the spleen indicated that *S. Typhi* could reside in dendritic cells (DCs), neutrophils, and B lymphocytes.²⁵⁵ Dendritic cells can capture bacteria from the lumen of the intestine. With the help of cell surface MHC II molecules and other costimulatory molecules like CD40 receptors, CD80, and CD86 ligands, DCs present bacterial antigens to the CD4 $^{+}$ helper T lymphocyte population and induce an adaptive immune response. While infecting murine DCs, *S. Typhimurium* delays the recruitment of NOX2 on SCV and impairs antigen presentation by K63-linked ubiquitination of MHC-II and subsequent degradation by endosomal proteases.²⁵⁶ *S. Typhimurium* infection in murine DCs enhances the expression and activity of iNOS (NOS2), which produces RNS to limit the growth of the bacteria in the SIRT2-dependent manner.²⁵⁷ During *S. Typhi* infection, intestinal inflammation is dictated by the pathogen and gut microbiota's interactions with intestinal DCs. The coinfection of intestinal DCs with a probiotic strain of *Bifidobacterium breve* CNCM I-4034 and human pathogen *S. Typhi* enhanced the expression of proinflammatory cytokines and chemokines like TNF- α , IL-8, and RANTES in a TLR-2-dependent manner.²⁵⁸ Infection of bone marrow-derived dendritic cells (BMDCs) with *S. Typhi* bacterial ghost (STG, which is an inactivated vaccine candidate expressing the *lysisE* gene from DNA phage ϕ X174), triggered the maturation of CD11c $^{+}$ BMDCs by increasing the expression of CD40, CD80, and MHC-II molecules.²⁵⁹ Furthermore, in DCs, the viable *S. Typhi* deploys several virulence factors to manipulate the host signaling process to favor its growth. The pR_{ST98} of *S. Typhi* suppresses the surface expression of several costimulatory molecules, such as CD40, CD80, and CD86, inhibiting autophagy in DCs. Wild-type *S. Typhi* can escape the Th1 response by downregulating IL-12 and IFN- γ and upregulating IL-10.²⁶⁰ In line with this observation, BALB/c mice infected with *S. Typhimurium* SR11 x3337 bearing the pR_{ST98} plasmid of *S. Typhi* showed suppression of dendritic and T cell activation.²⁶¹ On the contrary, human dendritic cells cocultured with the PBMCs infected with *S. Typhi* produced a higher level of proinflammatory cytokines like 12p70 and IFN- γ and augmented the antigen presentation to primed CD3 $^{+}$ and CD8 $^{+}$ effector/memory T cells.²⁶² *S. Typhi* utilizes TviA, a regulatory protein associated with flagellin expression (*fliC*), to invade the intestinal mucosa and escape antigen presentation by dendritic cells. The expression of *S. Typhi* TviA in *S. Typhimurium* diminished antigen presentation by dendritic cells to CD4 $^{+}$ T lymphocytes by lowering the availability of flagellar antigen in the *Nramp*^{+/+} CS7BL/6 mouse.²⁶³ However, the complex behavior of *S. Typhi* in dendritic cells has been poorly understood, and a considerable amount of research is required to unveil the mechanisms employed by the pathogen to modulate DCs and to thrive inside an otherwise hostile niche. Table 3 summarizes the strategies that *Salmonella* uses to emerge as a successful pathogen.




Figure 4. Extra-intestinal infections caused by *Salmonella* Typhi. The spleen is located behind the stomach, and kidneys are located at the back of the trunk's middle and have been marked accordingly. The percentage of occurrence is expressed concerning total gastrointestinal infections caused by the pathogen.

■ EXTRA-INTESTINAL INFECTIONS CAUSED BY *S. TYPHI*

Salmonella multiplies in reticuloendothelial cells and macrophages of the liver, spleen, lymph nodes, and bone marrow during the asymptomatic phase of infection. If left untreated, bacteria reach a threshold level and are released in the blood, initiating secondary bacteremia with cytokine secretion during the symptomatic phase of typhoid fever.²⁶⁴ This secondary persistent bacteremia phase leads to the seeding of other organs, which may further complicate the situation by developing intestinal perforations, hepatitis, pneumonia, and tissue abscesses, usually during the second and fourth weeks of illness.^{40,41,265,266}

Hence, it will be appropriate to comment that once bacteremia sets in following an *S. Typhi* infection, almost all organs have the potential to host bacterial foci. Quite frequently diagnosis of this infection is ignored, which leads

to fatal outcomes. Imaging techniques such as magnetic resonance imaging (MRI), ultrasonography (USG), and radiographs have facilitated the diagnostic process. MRI is a medical imaging technique used in radiology, and it can visualize the anatomy and physiological processes of the body. USG can help diagnose systemic manifestations like enlarged mesenteric lymph nodes (MLNs), mural thickening of terminal patients, splenomegaly, and acute acalculous cholecystitis associated with *Salmonella* infection. However, culturing the pathogen from the site of infection is the ultimate gold-standard diagnostic tool. Figure 4 and Table 4 demonstrate summaries of the extraintestinal infections of *Salmonella* and their manifestations.

■ CONCLUSION

Salmonella enterica infection remains a significant public health concern worldwide, especially in third-world countries where

Salmonella infection is often endemic due to various socio-economic factors. The history of epidemics, genetic makeup, and stealthy strategies against the host makes *Salmonella* a superbug. Its adaptation to infect a range of hosts often makes eradicating this notorious pathogen several times difficult. Despite significant progress in medical science over the last centuries, *Salmonella* causes significant mortality and morbidity pertaining mainly to its adaptation to host defense and the evolution of drug-resistant strains. *Salmonella* can cleverly manipulate host defense arsenals, thereby mounting an intense infection in the host system. This Review discussed the essential aspects that help the bacteria achieve this, especially horizontally acquired islands (SPIs). Therefore, understanding the biology of *Salmonella* infection is essential and will help us to reduce the burden of *Salmonella* infection globally.

Although typhoidal and nontyphoidal *Salmonella* serovars belong to the same biological species, these two serovars mount and trigger distinct acute infections in the host. The situation worsens due to extraintestinal manifestations, carriage, and recurrent infections in the population. The field of *Salmonella* biology has an immense amount of literature on understanding the molecular mechanisms of virulence. Nevertheless, there is a dearth of accurate information regarding the *in vivo* scenario due to host restrictions and the unavailability of permissive animal models. Therefore, there is a pressing need for a different animal model, a collaborative system of biology insights, and advanced techniques to decipher the systemic effects of *Salmonella* infection and single-cell approaches. This will further help us to develop plausible novel therapeutics and vaccination strategies against *Salmonella* infections.

■ AUTHOR INFORMATION

Corresponding Author

Dipshikha Chakravortty – Department of Microbiology and Cell Biology, Division of Biological Sciences, Indian Institute of Science, Bangalore, Karnataka 560012, India; Centre for Biosystems Science and Engineering, Indian Institute of Science, Bangalore, Karnataka 560012, India; Present Address: Adjunct Faculty - School of Biological Sciences, Indian Institute of Science Education and Research, Thiruvananthapuram, Kerala 695551, India; [ORCID iD: 0000-0002-7838-5145](https://orcid.org/0000-0002-7838-5145); Phone: 0091 80 2293 2842; Email: dipa@iisc.ac.in; Fax: 0091 80 2360 2697

Authors

Ritika Chatterjee – Department of Microbiology and Cell Biology, Division of Biological Sciences, Indian Institute of Science, Bangalore, Karnataka 560012, India

Atish Roy Chowdhury – Department of Microbiology and Cell Biology, Division of Biological Sciences, Indian Institute of Science, Bangalore, Karnataka 560012, India

Debapriya Mukherjee – Department of Microbiology and Cell Biology, Division of Biological Sciences, Indian Institute of Science, Bangalore, Karnataka 560012, India

Complete contact information is available at:

<https://pubs.acs.org/10.1021/acsomega.3c02386>

Author Contributions

#These authors contributed equally.

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

We are thankful for the financial support from the Department of Biotechnology (DBT) and Department of Science and Technology (DST), Ministry of Science and Technology. D.C. acknowledges DAE for the SRC outstanding investigator award and funds, a TATA fellowship, and ASTRA Chair Professorship funds. The authors jointly acknowledge the DBT-IISc Partnership Programme. Infrastructure support from ICMR (Center for Advanced Study in Molecular Medicine), DST (FIST), and UGC-CAS (special assistance) is acknowledged. R.C. duly acknowledges the CSIR-SRF fellowship. A.R.C. acknowledges Shamrao M. Kaikini and Krishna S. Kaikini's fellowship. D.M. acknowledges the IISc fellowship.

■ REFERENCES

- (1) Knodler, L. A.; Elfenbein, J. R. *Salmonella enterica*. *Trends Microbiol* **2019**, *27* (11), 964–965.
- (2) Mutz, Y. D. S.; et al. *Salmonella enterica*: A hidden risk for dry-cured meat consumption? *Crit Rev. Food Sci. Nutr* **2020**, *60* (6), 976–990.
- (3) Rau, R. B.; et al. *Salmonella enterica mcr-1 Positive from Food in Brazil: Detection and Characterization*. *Foodborne Pathog Dis* **2020**, *17* (3), 202–208.
- (4) Lamas, A.; et al. A comprehensive review of non-enterica subspecies of *Salmonella enterica*. *Microbiol Res* **2018**, *206*, 60–73.
- (5) Ferrari, R. G. Worldwide Epidemiology of *Salmonella* Serovars in Animal-Based Foods: a Meta-analysis. *Appl. Environ. Microbiol* **2019**, *85* (14), e00591-19.
- (6) Parkhill, J.; et al. Complete genome sequence of a multiple drug resistant *Salmonella enterica* serovar Typhi CT18. *Nature* **2001**, *413* (6858), 848–52.
- (7) Fookes, M.; et al. *Salmonella bongori* provides insights into the evolution of the *Salmonellae*. *PLoS Pathog* **2011**, *7* (8), No. e1002191.
- (8) Marks, F.; et al. Incidence of invasive salmonella disease in sub-Saharan Africa: a multicentre population-based surveillance study. *Lancet Glob Health* **2017**, *5* (3), e310–e323.
- (9) Schikora, A.; Garcia, A. V.; Hirt, H. Plants as alternative hosts for *Salmonella*. *Trends Plant Sci* **2012**, *17* (5), 245–9.
- (10) Jajere, S. M. A review of *Salmonella enterica* with particular focus on the pathogenicity and virulence factors, host specificity and antimicrobial resistance including multidrug resistance. *Vet World* **2019**, *12* (4), 504–521.
- (11) Afshari, A.; et al. *Salmonella Enteritidis* and *Salmonella Typhimurium* identification in poultry carcasses. *Iran J. Microbiol* **2018**, *10* (1), 45–50.
- (12) Stanaway, J. D.; et al. The global burden of non-typhoidal salmonella invasive disease: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet Infect Dis* **2019**, *19* (12), 1312–1324.
- (13) Feasey, N. A.; et al. Invasive non-typhoidal salmonella disease: an emerging and neglected tropical disease in Africa. *Lancet* **2012**, *379* (9835), 2489–2499.
- (14) Tack, B.; et al. Invasive non-typhoidal *Salmonella* infections in sub-Saharan Africa: a systematic review on antimicrobial resistance and treatment. *BMC Med* **2020**, *18*, 212.
- (15) Huang, D. B.; DuPont, H. L. Problem pathogens: extra-intestinal complications of *Salmonella enterica* serotype Typhi infection. *Lancet Infect Dis* **2005**, *5* (6), 341–8.
- (16) Chowdhury, A. R.; et al. Loss of outer membrane protein A (OmpA) impairs the survival of *Salmonella Typhimurium* by inducing membrane damage in the presence of ceftazidime and Meropenem. *J. Antimicrob. Chemother* **2022**, *77* (12), 3376–3389.
- (17) Majee, S.; et al. Spatiotemporal evaporating droplet dynamics on fomites enhances long term bacterial pathogenesis. *Commun. Biol.* **2021**, *4*, 1173.

- (18) Hariharan, V.; et al. phoP maintains the environmental persistence and virulence of pathogenic bacteria in mechanically stressed desiccated droplets. *iScience* **2023**, *26* (5), 106580.
- (19) Anstead, G. M. History, Rats, Fleas, and Opossums: The Ascendancy of Flea-Borne Typhus in the United States, 1910–1944. *Trop Med. Infect. Dis.* **2020**, *5* (1), 37.
- (20) MacLennan, C. A.; Martin, L. B.; Micoli, F. Vaccines against invasive Salmonella disease: current status and future directions. *Hum Vaccin Immunother* **2014**, *10* (6), 1478–93.
- (21) Stanaway, J. D.; et al. The global burden of typhoid and paratyphoid fevers: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet Infect Dis* **2019**, *19* (4), 369–381.
- (22) Kim, J. H.; et al. A Systematic Review of Typhoid Fever Occurrence in Africa. *Clin Infect Dis* **2019**, *69* (Supplement_6), S492–S498.
- (23) Meltzer, E.; Schwartz, E. Enteric fever: a travel medicine oriented view. *Curr. Opin Infect Dis* **2010**, *23* (5), 432–7.
- (24) Ochiai, R. L.; et al. Salmonella paratyphi A rates, Asia. *Emerg Infect Dis* **2005**, *11* (11), 1764–6.
- (25) Nässström, E.; et al. Salmonella Typhi and Salmonella Paratyphi A elaborate distinct systemic metabolite signatures during enteric fever. *Elife* **2014**, *3*, e03100.
- (26) Kuijpers, L. M. F.; et al. The clinical and microbiological characteristics of enteric fever in Cambodia, 2008–2015. *PLoS Negl Trop Dis* **2017**, *11* (9), No. e0005964.
- (27) Lynch, M. F.; et al. Typhoid fever in the United States, 1999–2006. *JAMA* **2009**, *302* (8), 859–65.
- (28) Woods, C. W.; et al. Emergence of *Salmonella enterica* serotype Paratyphi A as a major cause of enteric fever in Kathmandu, Nepal. *Trans R Soc. Trop Med. Hyg* **2006**, *100* (11), 1063–7.
- (29) Alvarez, M. I.; et al. Human genetic variation in VAC14 regulates *Salmonella* invasion and typhoid fever through modulation of cholesterol. *Proc. Natl. Acad. Sci. U. S. A.* **2017**, *114* (37), E7746–E7755.
- (30) Pier, G. B.; et al. *Salmonella typhi* uses CFTR to enter intestinal epithelial cells. *Nature* **1998**, *393* (6680), 79–82.
- (31) van de Vosse, E.; et al. Susceptibility to typhoid fever is associated with a polymorphism in the cystic fibrosis transmembrane conductance regulator (CFTR). *Hum. Genet.* **2005**, *118* (1), 138–40.
- (32) Marzel, A.; et al. Integrative analysis of *Salmonellosis* in Israel reveals association of *Salmonella enterica* Serovar 9,12:l,v:- with extraintestinal infections, dissemination of endemic *S. enterica* Serovar Typhimurium DT104 biotypes, and severe underreporting of outbreaks. *J. Clin Microbiol* **2014**, *52* (6), 2078–88.
- (33) Threlfall, E. J.; et al. Trends in antimicrobial drug resistance in *Salmonella enterica* serotypes Typhi and Paratyphi A isolated in Europe, 1999–2001. *Int. J. Antimicrob. Agents* **2003**, *22* (5), 487–91.
- (34) Gal-Mor, O.; Boyle, E. C.; Grassl, G. A. Same species, different diseases: how and why typhoidal and non-typhoidal *Salmonella enterica* serovars differ. *Front. Microbiol.* **2014**, *5*, 391.
- (35) Stevens, M. P.; Humphrey, T. J.; Maskell, D. J. Molecular insights into farm animal and zoonotic *Salmonella* infections. *Philos. Trans R Soc. Lond B Biol. Sci.* **2009**, *364* (1530), 2709–23.
- (36) Tsolis, R.; et al. From bench to bedside: Stealth of enteroinvasive pathogens. *Nature reviews. Microbiology* **2008**, *6*, 883–92.
- (37) Haselbeck, A. H.; et al. Current perspectives on invasive nontyphoidal *Salmonella* disease. *Curr. Opin Infect Dis* **2017**, *30* (5), 498–503.
- (38) Edelman, R.; Levine, M. M. Summary of an international workshop on typhoid fever. *Rev. Infect Dis* **1986**, *8* (3), 329–49.
- (39) Miguet, E.; Cormack, J. R. Miguet and Cormack on Creosote. *Edinb. Med. Surg J.* **1836**, *46* (129), 428–442.
- (40) Crump, J. A.; et al. Epidemiology, Clinical Presentation, Laboratory Diagnosis, Antimicrobial Resistance, and Antimicrobial Management of Invasive *Salmonella* Infections. *Clin Microbiol Rev* **2015**, *28* (4), 901–37.
- (41) Parry, C. M.; et al. Typhoid fever. *N Engl J. Med.* **2002**, *347* (22), 1770–82.
- (42) Humphries, R. M.; Linscott, A. J. Practical Guidance for Clinical Microbiology Laboratories: Diagnosis of Bacterial Gastroenteritis. *Clin Microbiol Rev* **2015**, *28* (1), 3–31.
- (43) Brenner, F. W.; et al. *Salmonella* nomenclature. *J. Clin Microbiol* **2000**, *38* (7), 2465–7.
- (44) Liu, B.; et al. Structural diversity in *Salmonella* O antigens and its genetic basis. *FEMS Microbiol Rev* **2014**, *38* (1), 56–89.
- (45) Issenhuth-Jeanjean, S.; et al. Supplement 2008–2010 (no. 48) to the White-Kauffmann-Le Minor scheme. *Res. Microbiol* **2014**, *165* (7), 526–30.
- (46) Schwartz, D. C.; Cantor, C. R. Separation of yeast chromosome-sized DNAs by pulsed field gradient gel electrophoresis. *Cell* **1984**, *37* (1), 67–75.
- (47) Gerner-Smidt, P.; et al. PulseNet USA: a five-year update. *Foodborne Pathog Dis* **2006**, *3* (1), 9–19.
- (48) Esteban, E.; et al. Use of ribotyping for characterization of *Salmonella* serotypes. *J. Clin Microbiol* **1993**, *31* (2), 233–7.
- (49) Fabre, L.; et al. CRISPR typing and subtyping for improved laboratory surveillance of *Salmonella* infections. *PLoS One* **2012**, *7* (5), No. e36995.
- (50) Liu, F.; et al. Novel virulence gene and clustered regularly interspaced short palindromic repeat (CRISPR) multilocus sequence typing scheme for subtyping of the major serovars of *Salmonella enterica* subsp. *enterica*. *Appl. Environ. Microbiol.* **2011**, *77* (6), 1946–56.
- (51) Achtman, M.; et al. Multilocus sequence typing as a replacement for serotyping in *Salmonella enterica*. *PLoS Pathog* **2012**, *8* (6), No. e1002776.
- (52) Sullivan, C. B.; Diggle, M. A.; Clarke, S. C. Multilocus sequence typing. *Molecular Biotechnology* **2005**, *29* (3), 245.
- (53) Ley, B.; et al. Evaluation of the Widal tube agglutination test for the diagnosis of typhoid fever among children admitted to a rural hospital in Tanzania and a comparison with previous studies. *BMC Infect Dis* **2010**, *10*, 180.
- (54) Olopoenia, L. A.; King, A. L. Widal agglutination test - 100 years later: still plagued by controversy. *Postgrad Med. J.* **2000**, *76* (892), 80–4.
- (55) Thriemer, K.; et al. A systematic review and meta-analysis of the performance of two point of care typhoid fever tests, Tubex TF and Typhidot, in endemic countries. *PLoS One* **2013**, *8* (12), No. e81263.
- (56) Wijedoru, L.; Mallett, S.; Parry, C. M.; et al. Rapid diagnostic tests for typhoid and paratyphoid (enteric) fever. *Cochrane Database Syst. Rev.* **2017**, *5*, CD008892.
- (57) Shukla, S.; Chitnis, D. S. Haemagglutination system for the simultaneous detection of LPS and anti LPS antibodies of *S.typhi*. *Indian J. Med. Sci.* **1997**, *51* (8), 265–269.
- (58) Kalhan, R.; et al. Rapid diagnosis of typhoid fever. *Indian Journal of Pediatrics* **1998**, *65* (4), 561–564.
- (59) Lin, L. H.; et al. Rectal swab sampling followed by an enrichment culture-based real-time PCR assay to detect *Salmonella enterocolitis* in children. *Clin Microbiol Infect* **2011**, *17* (9), 1421–5.
- (60) Tennant, S. M.; et al. Identification by PCR of non-typhoidal *Salmonella enterica* serovars associated with invasive infections among febrile patients in Mali. *PLoS Negl Trop Dis* **2010**, *4* (3), No. e621.
- (61) Song, J. H.; et al. Detection of *Salmonella typhi* in the blood of patients with typhoid fever by polymerase chain reaction. *J. Clin Microbiol* **1993**, *31* (6), 1439–43.
- (62) Ali, A.; et al. Multiplex PCR for differential diagnosis of emerging typhoidal pathogens directly from blood samples. *Epidemiol Infect* **2009**, *137* (1), 102–7.
- (63) Kumar, A.; et al. Detection of *Salmonella typhi* by polymerase chain reaction: implications in diagnosis of typhoid fever. *Infect Genet Evol* **2002**, *2* (2), 107–10.
- (64) Prakash, P.; et al. Evaluation of nested PCR in diagnosis of typhoid fever. *J. Clin Microbiol* **2005**, *43* (1), 431–2.
- (65) Nga, T. V.; et al. The sensitivity of real-time PCR amplification targeting invasive *Salmonella* serovars in biological specimens. *BMC Infect Dis* **2010**, *10*, 125.

- (66) Kumar, G.; et al. Use of urine with nested PCR targeting the flagellin gene (*fliC*) for diagnosis of typhoid fever. *J. Clin Microbiol* 2012, 50 (6), 1964–7.
- (67) Darton, T. C.; et al. Blood culture-PCR to optimize typhoid fever diagnosis after controlled human infection identifies frequent asymptomatic cases and evidence of primary bacteraemia. *J. Infect* 2017, 74 (4), 358–366.
- (68) Sanchez-Jimenez, M. M.; Cardona-Castro, N. Validation of a PCR for diagnosis of typhoid fever and salmonellosis by amplification of the *hilA* gene in clinical samples from Colombian patients. *J. Med. Microbiol* 2004, 53, 875–878.
- (69) Van Lint, P.; et al. Evaluation of a real-time multiplex PCR for the simultaneous detection of *Campylobacter jejuni*, *Salmonella* spp., *Shigella* spp./*EIEC*, and *Yersinia enterocolitica* in fecal samples. *Eur. J. Clin Microbiol Infect Dis* 2015, 34 (3), 535–42.
- (70) Kumar, A.; et al. Quick PCR based diagnosis of typhoid using specific genetic markers. *Biotechnol. Lett.* 2010, 32 (5), 707–12.
- (71) Khare, R.; et al. Comparative evaluation of two commercial multiplex panels for detection of gastrointestinal pathogens by use of clinical stool specimens. *J. Clin Microbiol* 2014, 52 (10), 3667–73.
- (72) Anderson, N. W.; Buchan, B. W.; Ledebroer, N. A. Comparison of the BD MAX enteric bacterial panel to routine culture methods for detection of *Campylobacter*, *enterohemorrhagic Escherichia coli* (O157), *Salmonella*, and *Shigella* isolates in preserved stool specimens. *J. Clin Microbiol* 2014, 52 (4), 1222–4.
- (73) He, Y.; et al. Mass spectrometry biotyping system identifies enteric bacterial pathogens directly from colonies grown on selective stool culture media. *J. Clin Microbiol* 2010, 48 (11), 3888–92.
- (74) Pang, S.; et al. Genetic relationships of phage types and single nucleotide polymorphism typing of *Salmonella enterica* Serovar Typhimurium. *J. Clin Microbiol* 2012, 50 (3), 727–34.
- (75) Schork, N. J.; Fallin, D.; Lanchbury, J. S. Single nucleotide polymorphisms and the future of genetic epidemiology. *Clin Genet* 2000, 58 (4), 250–64.
- (76) Collins, A.; Lonjou, C.; Morton, N. E. Genetic epidemiology of single-nucleotide polymorphisms. *Proc. Natl. Acad. Sci. U. S. A.* 1999, 96 (26), 15173–7.
- (77) Fritsche, G.; et al. *Slc11a1* (*Nramp1*) impairs growth of *Salmonella enterica* serovar *typhimurium* in macrophages via stimulation of lipocalin-2 expression. *J. Leukoc Biol.* 2012, 92 (2), 353–9.
- (78) Stecher, B.; et al. Chronic *Salmonella enterica* serovar Typhimurium-induced colitis and cholangitis in streptomycin-pre-treated *Nramp1*+/+ mice. *Infect. Immun.* 2006, 74 (9), 5047–57.
- (79) Cunrath, O.; Bumann, D. Host resistance factor SLC11A1 restricts *Salmonella* growth through magnesium deprivation. *Science* 2019, 366 (6468), 995–999.
- (80) McClelland, M.; et al. Complete genome sequence of *Salmonella enterica* serovar Typhimurium LT2. *Nature* 2001, 413 (6858), 852–6.
- (81) Mian, M. F.; et al. Humanized mice for *Salmonella typhi* infection: new tools for an old problem. *Virulence* 2011, 2 (3), 248–52.
- (82) Song, J.; et al. A mouse model for the human pathogen *Salmonella typhi*. *Cell Host Microbe* 2010, 8 (4), 369–76.
- (83) Firoz Mian, M.; et al. Humanized mice are susceptible to *Salmonella typhi* infection. *Cell Mol. Immunol* 2011, 8 (1), 83–7.
- (84) Libby, S. J.; et al. Humanized nonobese diabetic-scid IL2rgamma null mice are susceptible to lethal *Salmonella Typhi* infection. *Proc. Natl. Acad. Sci. U. S. A.* 2010, 107 (35), 15589–94.
- (85) Nickerson, C. A.; et al. Three-dimensional tissue assemblies: novel models for the study of *Salmonella enterica* serovar Typhimurium pathogenesis. *Infect. Immun.* 2001, 69 (11), 7106–20.
- (86) Zhang, Y. G.; et al. *Salmonella*-infected crypt-derived intestinal organoid culture system for host-bacterial interactions. *Physiol Rep* 2014, 2 (9), e12147.
- (87) Wilson, S. S.; et al. A small intestinal organoid model of non-invasive enteric pathogen-epithelial cell interactions. *Mucosal Immunol* 2015, 8 (2), 352–61.
- (88) Farin, H. F.; et al. Paneth cell extrusion and release of antimicrobial products is directly controlled by immune cell-derived IFN-gamma. *J. Exp. Med.* 2014, 211 (7), 1393–405.
- (89) Nickerson, K. P.; et al. *Salmonella Typhi* Colonization Provokes Extensive Transcriptional Changes Aimed at Evading Host Mucosal Immune Defense During Early Infection of Human Intestinal Tissue. *EBioMedicine* 2018, 31, 92–109.
- (90) Chandra, K.; et al. GH18 family glycoside hydrolase Chitinase A of *Salmonella* enhances virulence by facilitating invasion and modulating host immune responses. *PLoS Pathog* 2022, 18 (4), No. e1010407.
- (91) Prouty, A. M.; et al. Bile-salt-mediated induction of antimicrobial and bile resistance in *Salmonella typhimurium*. *Microbiology* 2004, 150 (4), 775–783.
- (92) Richards, A. F.; et al. Inhibition of invasive *salmonella* by orally administered IgA and IgG monoclonal antibodies. *PLoS Negl Trop Dis* 2020, 14 (3), No. e0007803.
- (93) Michetti, P.; et al. Monoclonal secretory immunoglobulin A protects mice against oral challenge with the invasive pathogen *Salmonella typhimurium*. *Infect. Immun.* 1992, 60 (5), 1786–92.
- (94) Selsted, M. E.; et al. Enteric defensins: antibiotic peptide components of intestinal host defense. *J. Cell Biol.* 1992, 118 (4), 929–36.
- (95) Matamouros, S.; Miller, S. Typhimurium strategies to resist killing by cationic antimicrobial peptides. *Biochim. Biophys. Acta* 2015, 1848 (11), 3021–3025.
- (96) Garcia-del Portillo, F.; Foster, J. W.; Finlay, B. B. Role of acid tolerance response genes in *Salmonella typhimurium* virulence. *Infect. Immun.* 1993, 61 (10), 4489–92.
- (97) Suar, M.; Ryan, D. Small RNA in the acid tolerance response of *Salmonella* and their role in virulence. *Virulence* 2015, 6 (2), 105–6.
- (98) Kohbata, S.; Yokoyama, H.; Yabuuchi, E. Cytopathogenic effect of *Salmonella typhi* GIFU 10007 on M cells of murine ileal Peyer's patches in ligated ileal loops: an ultrastructural study. *Microbiol. Immunol.* 1986, 30 (12), 1225–37.
- (99) Jones, B. D.; Ghori, N.; Falkow, S. *Salmonella typhimurium* initiates murine infection by penetrating and destroying the specialized epithelial M cells of the Peyer's patches. *J. Exp. Med.* 1994, 180 (1), 15–23.
- (100) Vazquez-Torres, A.; et al. Extraintestinal dissemination of *Salmonella* by CD18-expressing phagocytes. *Nature* 1999, 401 (6755), 804–8.
- (101) Haraga, A.; Ohlson, M. B.; Miller, S. I. *Salmonellae* interplay with host cells. *Nat. Rev. Microbiol* 2008, 6 (1), 53–66.
- (102) Bader, M. W.; et al. Regulation of *Salmonella typhimurium* virulence gene expression by cationic antimicrobial peptides. *Mol. Microbiol.* 2003, 50 (1), 219–30.
- (103) Miao, E. A.; Freeman, J. A.; Miller, S. I. Transcription of the *SsrAB* regulon is repressed by alkaline pH and is independent of *PhoPQ* and magnesium concentration. *J. Bacteriol.* 2002, 184 (5), 1493–7.
- (104) Vazquez-Torres, A.; et al. *Salmonella* pathogenicity island 2-dependent evasion of the phagocyte NADPH oxidase. *Science* 2000, 287 (5458), 1655–8.
- (105) Shea, J. E.; et al. Identification of a virulence locus encoding a second type III secretion system in *Salmonella typhimurium*. *Proc. Natl. Acad. Sci. U. S. A.* 1996, 93 (6), 2593–7.
- (106) Ochman, H.; et al. Identification of a pathogenicity island required for *Salmonella* survival in host cells. *Proc. Natl. Acad. Sci. U. S. A.* 1996, 93 (15), 7800–4.
- (107) Alpuche-Aranda, C. M.; et al. *Salmonella* stimulate macrophage macropinocytosis and persist within spacious phagosomes. *J. Exp. Med.* 1994, 179 (2), 601–8.
- (108) Alpuche Aranda, C. M.; et al. *Salmonella typhimurium* activates virulence gene transcription within acidified macrophage phagosomes. *Proc. Natl. Acad. Sci. U. S. A.* 1992, 89 (21), 10079–83.
- (109) Miller, S. I.; Kukral, A. M.; Mekalanos, J. J. A two-component regulatory system (*phoP phoQ*) controls *Salmonella typhimurium* virulence. *Proc. Natl. Acad. Sci. U. S. A.* 1989, 86 (13), 5054–8.

- (110) Watson, C. H.; et al. A cross-sectional seroepidemiological survey of typhoid fever in Fiji. *PLoS Negl Trop Dis* **2017**, *11* (7), No. e0005786.
- (111) Zhong, M.; Yan, H.; Li, Y. Flagellin: a unique microbe-associated molecular pattern and a multi-faceted immunomodulator. *Cell Mol. Immunol.* **2017**, *14* (10), 862–864.
- (112) Elhadad, D.; et al. Flagellin Is Required for Host Cell Invasion and Normal Salmonella Pathogenicity Island 1 Expression by *Salmonella enterica* Serovar Paratyphi A. *Infect. Immun.* **2015**, *83* (9), 3355–68.
- (113) Tran, Q. T.; et al. The *Salmonella enterica* serotype Typhi Vi capsular antigen is expressed after the bacterium enters the ileal mucosa. *Infect. Immun.* **2010**, *78* (1), 527–35.
- (114) Zhang, X. L.; Jeza, V. T.; Pan, Q. *Salmonella typhi*: from a human pathogen to a vaccine vector. *Cell Mol. Immunol.* **2008**, *5* (2), 91–7.
- (115) Santos, R. L.; et al. Pathogenesis of *Salmonella*-induced enteritis. *Braz. J. Med. Biol. Res.* **2003**, *36* (1), 3–12.
- (116) Schmidt, H.; Hensel, M. Pathogenicity islands in bacterial pathogenesis. *Clin Microbiol Rev.* **2004**, *17* (1), 14–56.
- (117) Ilyas, B.; Tsai, C. N.; Coombes, B. K. Evolution of *Salmonella*-Host Cell Interactions through a Dynamic Bacterial Genome. *Front Cell Infect Microbiol* **2017**, *7*, 428.
- (118) Cheng, R. A.; Eade, C. R.; Wiedmann, M. Embracing Diversity: Differences in Virulence Mechanisms, Disease Severity, and Host Adaptations Contribute to the Success of Nontyphoidal *Salmonella* as a Foodborne Pathogen. *Front. Microbiol.* **2019**, *10*, 1368.
- (119) Siriken, B. [Salmonella pathogenicity islands]. *Mikrobiyol Bul* **2013**, *47* (1), 181–8.
- (120) Sabbagh, S. C.; et al. So similar, yet so different: uncovering distinctive features in the genomes of *Salmonella enterica* serovars Typhimurium and Typhi. *FEMS Microbiol Lett.* **2010**, *305* (1), 1–13.
- (121) Shah, D. H.; et al. Identification of *Salmonella gallinarum* virulence genes in a chicken infection model using PCR-based signature-tagged mutagenesis. *Microbiology* **2005**, *151* (12), 3957–3968.
- (122) Galyov, E. E.; et al. A secreted effector protein of *Salmonella dublin* is translocated into eukaryotic cells and mediates inflammation and fluid secretion in infected ileal mucosa. *Mol. Microbiol.* **1997**, *25* (5), 903–12.
- (123) Johnson, R.; Mylona, E.; Frankel, G. Typhoidal *Salmonella*: Distinctive virulence factors and pathogenesis. *Cell Microbiol* **2018**, *20* (9), No. e12939.
- (124) Collazo, C. M.; Galan, J. E. The invasion-associated type-III protein secretion system in *Salmonella*—a review. *Gene* **1997**, *192* (1), 51–9.
- (125) Galan, J. E.; Curtiss, R., 3rd Cloning and molecular characterization of genes whose products allow *Salmonella typhimurium* to penetrate tissue culture cells. *Proc. Natl. Acad. Sci. U. S. A.* **1989**, *86* (16), 6383–7.
- (126) Zhou, D.; et al. A *Salmonella* inositol polyphosphatase acts in conjunction with other bacterial effectors to promote host cell actin cytoskeleton rearrangements and bacterial internalization. *Mol. Microbiol.* **2001**, *39* (2), 248–59.
- (127) Piscatelli, H. L.; Li, M.; Zhou, D. Dual 4- and 5-phosphatase activities regulate SopB-dependent phosphoinositide dynamics to promote bacterial entry. *Cellular Microbiology* **2016**, *18* (5), 705–719.
- (128) Mallo, G. V.; et al. SopB promotes phosphatidylinositol 3-phosphate formation on *Salmonella* vacuoles by recruiting Rab5 and Vps34. *J. Cell Biol.* **2008**, *182* (4), 741–52.
- (129) Chatterjee, R.; et al. Deceiving The Big Eaters: *Salmonella Typhimurium* SopB subverts host cell Xenophagy in macrophages via dual mechanisms. *Microbes and Infection* **2023**, *25*, 105128.
- (130) Patel, J. C.; Galan, J. E. Differential activation and function of Rho GTPases during *Salmonella*-host cell interactions. *J. Cell Biol.* **2006**, *175* (3), 453–63.
- (131) Knodler, L. A.; Finlay, B. B.; Steele-Mortimer, O. The *Salmonella* effector protein SopB protects epithelial cells from apoptosis by sustained activation of Akt. *J. Biol. Chem.* **2005**, *280* (10), 9058–64.
- (132) Garcia-Gil, A.; et al. SopB activates the Akt-YAP pathway to promote *Salmonella* survival within B cells. *Virulence* **2018**, *9* (1), 1390–1402.
- (133) Stender, S.; et al. Identification of SopE2 from *Salmonella typhimurium*, a conserved guanine nucleotide exchange factor for Cdc42 of the host cell. *Mol. Microbiol.* **2000**, *36* (6), 1206–21.
- (134) Friebel, A.; et al. SopE and SopE2 from *Salmonella typhimurium* activate different sets of RhoGTPases of the host cell. *J. Biol. Chem.* **2001**, *276* (36), 34035–40.
- (135) Hardt, W. D.; et al. *S. typhimurium* encodes an activator of Rho GTPases that induces membrane ruffling and nuclear responses in host cells. *Cell* **1998**, *93* (5), 815–26.
- (136) Hayward, R. D.; Koronakis, V. Direct nucleation and bundling of actin by the SipC protein of invasive *Salmonella*. *EMBO J.* **1999**, *18* (18), 4926–34.
- (137) Collazo, C. M.; Galan, J. E. The invasion-associated type III system of *Salmonella typhimurium* directs the translocation of Sip proteins into the host cell. *Mol. Microbiol.* **1997**, *24* (4), 747–56.
- (138) Kaniga, K.; et al. Homologs of the *Shigella* IpaB and IpaC invasins are required for *Salmonella typhimurium* entry into cultured epithelial cells. *J. Bacteriol.* **1995**, *177* (14), 3965–71.
- (139) McGhie, E. J.; Hayward, R. D.; Koronakis, V. Control of Actin Turnover by a *Salmonella* Invasion Protein. *Mol. Cell* **2004**, *13* (4), 497–510.
- (140) McGhie, E. J.; Hayward, R. D.; Koronakis, V. Cooperation between actin-binding proteins of invasive *Salmonella*: SipA potentiates SipC nucleation and bundling of actin. *EMBO Journal* **2001**, *20* (9), 2131–2139.
- (141) Jepson, M. A.; Kenny, B.; Leard, A. D. Role of sipA in the early stages of *Salmonella typhimurium* entry into epithelial cells. *Cell Microbiol* **2001**, *3* (6), 417–26.
- (142) Fattinger, S. A.; et al. *Salmonella Typhimurium* discreet-invasion of the murine gut absorptive epithelium. *PLoS Pathog* **2020**, *16* (5), No. e1008503.
- (143) Hersh, D.; et al. The *Salmonella* invasin SipB induces macrophage apoptosis by binding to caspase-1. *Proc. Natl. Acad. Sci. U. S. A.* **1999**, *96* (5), 2396–401.
- (144) Dreher, D.; et al. *Salmonella* virulence factor SipB induces activation and release of IL-18 in human dendritic cells. *J. Leukoc Biol.* **2002**, *72* (4), 743–51.
- (145) Obregon, C.; et al. Human alveolar macrophages infected by virulent bacteria expressing SipB are a major source of active interleukin-18. *Infect. Immun.* **2003**, *71* (8), 4382–8.
- (146) Eswarappa, S. M.; et al. Differentially evolved genes of *Salmonella* pathogenicity islands: insights into the mechanism of host specificity in *Salmonella*. *PLoS One* **2008**, *3* (12), No. e3829.
- (147) Altier, C. Genetic and environmental control of salmonella invasion. *J. Microbiol* **2005**, *43*, 85–92.
- (148) Altier, C.; et al. Characterization of two novel regulatory genes affecting *Salmonella* invasion gene expression. *Mol. Microbiol.* **2000**, *35* (3), 635–46.
- (149) Prouty, A. M.; Gunn, J. S. *Salmonella enterica* serovar typhimurium invasion is repressed in the presence of bile. *Infect. Immun.* **2000**, *68* (12), 6763–9.
- (150) Ellermeier, J. R.; Slauch, J. M. Adaptation to the host environment: regulation of the SPI1 type III secretion system in *Salmonella enterica* serovar Typhimurium. *Curr. Opin Microbiol* **2007**, *10* (1), 24–9.
- (151) Johnson, R.; et al. Comparison of *Salmonella enterica* Serovars Typhi and Typhimurium Reveals Typhoidal Serovar-Specific Responses to Bile. *Infect. Immun.* **2018**, *86*, No. e00490-17.
- (152) Elhadad, D.; et al. Feverlike Temperature is a Virulence Regulatory Cue Controlling the Motility and Host Cell Entry of Typhoidal *Salmonella*. *J. Infect Dis* **2015**, *212* (1), 147–56.
- (153) Niklaus, T.; et al. SseBCD proteins are secreted by the type III secretion system of *Salmonella* pathogenicity island 2 and function as a translocon. *J. Bacteriol.* **2001**, *183* (20), 6036–45.

- (154) Yu, X. J.; et al. pH sensing by intracellular *Salmonella* induces effector translocation. *Science* **2010**, *328* (5981), 1040–3.
- (155) Chatterjee, R.; et al. Enteropathogens: Tuning Their Gene Expression for Hassle-Free Survival. *Front. Microbiol.* **2019**, *9*, 3303.
- (156) LaRock, D. L.; Chaudhary, A.; Miller, S. I. *Salmonellae* interactions with host processes. *Nat. Rev. Microbiol.* **2015**, *13* (4), 191–205.
- (157) Figueira, R.; Holden, D. W. Functions of the *Salmonella* pathogenicity island 2 (SPI-2) type III secretion system effectors. *Microbiology* **2012**, *158* (5), 1147–1161.
- (158) Galan, J. E. *Salmonella* interactions with host cells: type III secretion at work. *Annu. Rev. Cell Dev. Biol.* **2001**, *17*, 53–86.
- (159) Steele-Mortimer, O.; et al. Activation of Akt/protein kinase B in epithelial cells by the *Salmonella typhimurium* effector sigD. *J. Biol. Chem.* **2000**, *275* (48), 37718–24.
- (160) Malik-Kale, P.; et al. *Salmonella* - at home in the host cell. *Front. Microbiol.* **2011**, *2*, 125.
- (161) Terebiznik, M. R.; et al. Elimination of host cell PtdIns(4,5)-P₂ by bacterial SigD promotes membrane fission during invasion by *Salmonella*. *Nat. Cell Biol.* **2002**, *4* (10), 766–73.
- (162) McGhie, E. J.; et al. *Salmonella* takes control: effector-driven manipulation of the host. *Curr. Opin Microbiol.* **2009**, *12* (1), 117–24.
- (163) Liebl, D.; et al. SopB-Mediated Recruitment of SNX18 Facilitates *Salmonella Typhimurium* Internalization by the Host Cell. *Front. Cell. Infect. Microbiol.* **2017**, *7*, 257.
- (164) Smith, A. C.; et al. Interaction of the *Salmonella*-containing vacuole with the endocytic recycling system. *J. Biol. Chem.* **2005**, *280* (26), 24634–41.
- (165) Steele-Mortimer, O.; et al. Biogenesis of *Salmonella typhimurium*-containing vacuoles in epithelial cells involves interactions with the early endocytic pathway. *Cell Microbiol.* **1999**, *1* (1), 33–49.
- (166) Meresse, S.; et al. Controlling the maturation of pathogen-containing vacuoles: a matter of life and death. *Nat. Cell Biol.* **1999**, *1* (7), E183–8.
- (167) Meresse, S.; et al. The rab7 GTPase controls the maturation of *Salmonella typhimurium*-containing vacuoles in HeLa cells. *EMBO J.* **1999**, *18* (16), 4394–403.
- (168) Garcia-del Portillo, F.; Finlay, B. B. Targeting of *Salmonella typhimurium* to vesicles containing lysosomal membrane glycoproteins bypasses compartments with mannose 6-phosphate receptors. *J. Cell Biol.* **1995**, *129* (1), 81–97.
- (169) Drecktrah, D.; et al. *Salmonella* trafficking is defined by continuous dynamic interactions with the endolysosomal system. *Traffic* **2007**, *8* (3), 212–25.
- (170) Beuzon, C. R.; et al. *Salmonella* maintains the integrity of its intracellular vacuole through the action of SifA. *EMBO J.* **2000**, *19* (13), 3235–49.
- (171) Mostowy, S.; et al. p62 and NDP52 proteins target intracytosolic *Shigella* and *Listeria* to different autophagy pathways. *J. Biol. Chem.* **2011**, *286* (30), 26987–95.
- (172) Pankiv, S.; et al. FYCO1 is a Rab7 effector that binds to LC3 and PI3P to mediate microtubule plus end-directed vesicle transport. *J. Cell Biol.* **2010**, *188* (2), 253–69.
- (173) Harrison, R. E.; et al. *Salmonella* impairs RILP recruitment to Rab7 during maturation of invasion vacuoles. *Mol. Biol. Cell* **2004**, *15* (7), 3146–54.
- (174) Brumell, J. H.; et al. Characterization of *Salmonella*-Induced Filaments (Sifs) Reveals a Delayed Interaction Between *Salmonella*-Containing Vacuoles and Late Endocytic Compartments. *Traffic* **2001**, *2* (9), 643–653.
- (175) Knodler, L. A.; Steele-Mortimer, O. The *Salmonella* effector PipB2 affects late endosome/lysosome distribution to mediate Sif extension. *Mol. Biol. Cell* **2005**, *16* (9), 4108–23.
- (176) McGourty, K.; et al. *Salmonella* inhibits retrograde trafficking of mannose-6-phosphate receptors and lysosome function. *Science* **2012**, *338* (6109), 963–7.
- (177) Jordens, I.; et al. The Rab7 effector protein RILP controls lysosomal transport by inducing the recruitment of dynein-dynactin motors. *Curr. Biol.* **2001**, *11* (21), 1680–1685.
- (178) Yu, X. J.; Liu, M.; Holden, D.W. *Salmonella* Effectors SseF and SseG Interact with Mammalian Protein ACBD3 (GCP60) To Anchor *Salmonella*-Containing Vacuoles at the Golgi Network. *mBio* **2016**, *7* (4), No. e00474-16.
- (179) Birmingham, C. L.; et al. Autophagy controls *Salmonella* infection in response to damage to the *Salmonella*-containing vacuole. *J. Biol. Chem.* **2006**, *281* (16), 11374–83.
- (180) Zhao, W.; et al. The *Salmonella* effector protein SifA plays a dual role in virulence. *Sci. Rep.* **2015**, *5*, 12979.
- (181) Rajashekhar, R.; et al. Dynamic remodeling of the endosomal system during formation of *Salmonella*-induced filaments by intracellular *Salmonella enterica*. *Traffic* **2008**, *9* (12), 2100–16.
- (182) Drecktrah, D.; et al. Dynamic behavior of *Salmonella*-induced membrane tubules in epithelial cells. *Traffic* **2008**, *9* (12), 2117–29.
- (183) Liss, V.; et al. *Salmonella enterica* Remodels the Host Cell Endosomal System for Efficient Intravacuolar Nutrition. *Cell Host Microbe* **2017**, *21* (3), 390–402.
- (184) Popp, J.; et al. Role of host cell-derived amino acids in nutrition of intracellular *Salmonella enterica*. *Infect. Immun.* **2015**, *83* (12), 4466–75.
- (185) Eswarappa, S. M.; et al. Division of the *Salmonella*-containing vacuole and depletion of acidic lysosomes in *Salmonella*-infected host cells are novel strategies of *Salmonella enterica* to avoid lysosomes. *Infect. Immun.* **2010**, *78* (1), 68–79.
- (186) Knodler, L. A.; Nair, V.; Steele-Mortimer, O. Quantitative assessment of cytosolic *Salmonella* in epithelial cells. *PLoS One* **2014**, *9* (1), No. e84681.
- (187) Malik-Kale, P.; Winfree, S.; Steele-Mortimer, O. The bimodal lifestyle of intracellular *Salmonella* in epithelial cells: replication in the cytosol obscures defects in vacuolar replication. *PLoS One* **2012**, *7* (6), No. e38732.
- (188) Perrin, A. J.; et al. Recognition of bacteria in the cytosol of Mammalian cells by the ubiquitin system. *Curr. Biol.* **2004**, *14* (9), 806–11.
- (189) Knodler, L. A.; et al. Dissemination of invasive *Salmonella* via bacterial-induced extrusion of mucosal epithelia. *Proc. Natl. Acad. Sci. U. S. A.* **2010**, *107* (41), 17733–8.
- (190) Singh, P. K.; et al. *Salmonella* SipA mimics a cognate SNARE for host Syntaxin8 to promote fusion with early endosomes. *J. Cell Biol.* **2018**, *217* (12), 4199–4214.
- (191) Stevenin, V.; et al. Dynamic Growth and Shrinkage of the *Salmonella*-Containing Vacuole Determines the Intracellular Pathogen Niche. *Cell Rep.* **2019**, *29* (12), 3958–3973.e7.
- (192) Chatterjee, R.; et al. Syntaxin 3 SPI-2 dependent crosstalk facilitates the division of *Salmonella* containing vacuole. *Traffic* **2023**, *24* (7), 270–283.
- (193) Madan, R.; et al. *Salmonella* acquires lysosome-associated membrane protein 1 (LAMP1) on phagosomes from Golgi via SipC protein-mediated recruitment of host Syntaxin6. *J. Biol. Chem.* **2012**, *287* (8), 5574–87.
- (194) Thurston, T. L.; et al. Galectin 8 targets damaged vesicles for autophagy to defend cells against bacterial invasion. *Nature* **2012**, *482* (7385), 414–8.
- (195) Chatterjee, R.; et al. Deceiving The Big Eaters: *Salmonella Typhimurium* SopB subverts host cell Xenophagy in macrophages via dual mechanisms. *Microbes Infect.* **2023**, *25*, 105128.
- (196) Gogoi, M.; Shreenivas, M. M.; Chakravortty, D. Hoodwinking the Big-Eater to Prosper: The *Salmonella*-Macrophage Paradigm. *J. Innate Immun.* **2019**, *11* (3), 289–299.
- (197) Srinivasan, A.; et al. Innate immune activation of CD4 T cells in salmonella-infected mice is dependent on IL-18. *J. Immunol.* **2007**, *178* (10), 6342–9.
- (198) Chavez-Arroyo, A.; Portnoy, D. A. Why is *Listeria* monocytopathic such a potent inducer of CD8+ T-cells? *Cell. Microbiol.* **2020**, *22* (4), No. e13175.

- (199) Rana, A.; et al. RIPK3 and Caspase-1/11 Are Necessary for Optimal Antigen-Specific CD8 T Cell Response Elicited by Genetically Modified Listeria monocytogenes. *Front. Immunol.* **2020**, *11*, 536.
- (200) Lee, S. J.; Dunmire, S.; McSorley, S. J. MHC class-I-restricted CD8 T cells play a protective role during primary Salmonella infection. *Immunol. Lett.* **2012**, *148* (2), 138–43.
- (201) Lopez-Medina, M.; et al. Salmonella impairs CD8 T cell response through PD-1: PD-L axis. *Immunobiology* **2015**, *220* (12), 1369–80.
- (202) Achouri, S.; et al. The frequency and duration of Salmonella-macrophage adhesion events determines infection efficiency. *Philos. Trans R Soc. Lond B Biol. Sci.* **2015**, *370* (1661), 20140033.
- (203) Lathrop, S. K.; et al. Replication of *Salmonella enterica* Serovar Typhimurium in Human Monocyte-Derived Macrophages. *Infect. Immun.* **2015**, *83* (7), 2661–71.
- (204) Ellis, M. J.; et al. A macrophage-based screen identifies antibacterial compounds selective for intracellular *Salmonella* Typhimurium. *Nat. Commun.* **2019**, *10*, 197.
- (205) Swart, A. L.; Hensel, M. Interactions of *Salmonella enterica* with dendritic cells. *Virulence* **2012**, *3* (7), 660–7.
- (206) Bueno, S. M.; et al. The capacity of *Salmonella* to survive inside dendritic cells and prevent antigen presentation to T cells is host specific. *Immunology* **2008**, *124* (4), 522–33.
- (207) Rosales-Reyes, R.; et al. Survival of *Salmonella enterica* serovar Typhimurium within late endosomal-lysosomal compartments of B lymphocytes is associated with the inability to use the vacuolar alternative major histocompatibility complex class I antigen-processing pathway. *Infect. Immun.* **2005**, *73* (7), 3937–44.
- (208) Souwer, Y.; et al. Selective infection of antigen-specific B lymphocytes by *Salmonella* mediates bacterial survival and systemic spreading of infection. *PLoS One* **2012**, *7* (11), No. e50667.
- (209) Lopez-Medina, M.; et al. *Salmonella* modulates B cell biology to evade CD8(+) T cell-mediated immune responses. *Front. Immunol.* **2014**, *5*, 586.
- (210) Xu, J.; et al. Single-Cell and Time-Resolved Profiling of Intracellular *Salmonella* Metabolism in Primary Human Cells. *Anal. Chem.* **2019**, *91* (12), 7729–7737.
- (211) Starr, T.; et al. The phorbol 12-myristate-13-acetate differentiation protocol is critical to the interaction of THP-1 macrophages with *Salmonella* Typhimurium. *PLoS One* **2018**, *13* (3), No. e0193601.
- (212) Singh, V.; Schwerk, P.; Tedin, K. Rapid Isolation of intact *Salmonella*-containing vacuoles using paramagnetic nanoparticles. *Gut Pathog.* **2018**, *10*, 33.
- (213) van der Heijden, J.; et al. Direct measurement of oxidative and nitrosative stress dynamics in *Salmonella* inside macrophages. *Proc. Natl. Acad. Sci. U. S. A.* **2015**, *112* (2), 560–5.
- (214) Balakrishnan, A.; Schnare, M.; Chakravortty, D. Of Men Not Mice: Bactericidal/Permeability-Increasing Protein Expressed in Human Macrophages Acts as a Phagocytic Receptor and Modulates Entry and Replication of Gram-Negative Bacteria. *Front. Immunol.* **2016**, *7*, 455.
- (215) Murret-Labarthe, C.; et al. New Roles for Two-Component System Response Regulators of *Salmonella enterica* Serovar Typhi during Host Cell Interactions. *Microorganisms* **2020**, *8* (5), 722.
- (216) Spano, S. Host restriction in *Salmonella*: insights from Rab GTPases. *Cell Microbiol.* **2014**, *16* (9), 1321–8.
- (217) Spano, S.; Galan, J. E. A Rab32-dependent pathway contributes to *Salmonella typhi* host restriction. *Science* **2012**, *338* (6109), 960–3.
- (218) Wachtel, R.; et al. The protease GtgE from *Salmonella* exclusively targets inactive Rab GTPases. *Nat. Commun.* **2018**, *9*, 44.
- (219) Galan, J. E. Typhoid toxin provides a window into typhoid fever and the biology of *Salmonella* Typhi. *Proc. Natl. Acad. Sci. U. S. A.* **2016**, *113* (23), 6338–44.
- (220) Spano, S.; et al. A Bacterial Pathogen Targets a Host Rab-Family GTPase Defense Pathway with a GAP. *Cell Host Microbe* **2016**, *19* (2), 216–26.
- (221) Dell'Angelica, E. C. The building BLOC(k)s of lysosomes and related organelles. *Curr. Opin Cell Biol.* **2004**, *16* (4), 458–64.
- (222) Chen, M.; et al. Itaconate is an effector of a Rab GTPase cell-autonomous host defense pathway against *Salmonella*. *Science* **2020**, *369* (6502), 450–455.
- (223) Lin, H. H.; et al. Hyperexpression of type III secretion system of *Salmonella* Typhi linked to a higher cytotoxic effect to monocyte-derived macrophages by activating inflammasome. *Microb. Pathog.* **2020**, *146*, 104222.
- (224) Gallois, A.; et al. *Salmonella* pathogenicity island 2-encoded type III secretion system mediates exclusion of NADPH oxidase assembly from the phagosomal membrane. *J. Immunol.* **2001**, *166* (9), 5741–8.
- (225) Forest, C. G.; et al. Intracellular survival of *Salmonella enterica* serovar Typhi in human macrophages is independent of *Salmonella* pathogenicity island (SPI)-2. *Microbiology* **2010**, *156* (12), 3689–3698.
- (226) Karlinsey, J. E.; et al. Genome-wide Analysis of *Salmonella enterica* serovar Typhi in Humanized Mice Reveals Key Virulence Features. *Cell Host Microbe* **2019**, *26* (3), 426–434.e6.
- (227) Ortega, A. P.; et al. Lose to win: marT pseudogenization in *Salmonella enterica* serovar Typhi contributed to the surV-dependent survival to H₂O₂, and inside human macrophage-like cells. *Infect. Genet. Evol.* **2016**, *45*, 111–121.
- (228) Wang, F.; et al. Type IVB pilated *Salmonella typhi* enhance IL-6 and NF-κappaB production in human monocytic THP-1 cells through activation of protein kinase C. *Immunobiology* **2005**, *210* (5), 283–93.
- (229) Pan, Q.; et al. Aptamers that preferentially bind type IVB pili and inhibit human monocytic-cell invasion by *Salmonella enterica* serovar typhi. *Antimicrob. Agents Chemother.* **2005**, *49* (10), 4052–60.
- (230) Spano, S.; Ugalde, J. E.; Galan, J. E. Delivery of a *Salmonella* Typhi exotoxin from a host intracellular compartment. *Cell Host Microbe* **2008**, *3* (1), 30–8.
- (231) Fowler, C. C.; Galan, J. E. Decoding a *Salmonella* Typhi Regulatory Network that Controls Typhoid Toxin Expression within Human Cells. *Cell Host Microbe* **2018**, *23* (1), 65–76.e6.
- (232) Chang, S. J.; Song, J.; Galan, J. E. Receptor-Mediated Sorting of Typhoid Toxin during Its Export from *Salmonella* Typhi-Infected Cells. *Cell Host Microbe* **2016**, *20* (5), 682–689.
- (233) Ibler, A. E. M.; et al. Typhoid toxin exhausts the RPA response to DNA replication stress driving senescence and *Salmonella* infection. *Nat. Commun.* **2019**, *10*, 4040.
- (234) Williams, K.; et al. Cytotoxic mechanism of cytolethal distending toxin in nontyphoidal *Salmonella* serovar (*Salmonella* Javiana) during macrophage infection. *DNA Cell Biol.* **2015**, *34* (2), 113–24.
- (235) Lee, S.; et al. *Salmonella* Typhoid Toxin PltB Subunit and Its Non-typhoidal *Salmonella* Ortholog Confer Differential Host Adaptation and Virulence. *Cell Host Microbe* **2020**, *27* (6), 937–949.e6.
- (236) Faucher, S. P.; et al. Transcriptome of *Salmonella enterica* serovar Typhi within macrophages revealed through the selective capture of transcribed sequences. *Proc. Natl. Acad. Sci. U. S. A.* **2006**, *103* (6), 1906–11.
- (237) Sabbagh, S. C.; et al. Selection of *Salmonella enterica* serovar Typhi genes involved during interaction with human macrophages by screening of a transposon mutant library. *PLoS One* **2012**, *7* (5), No. e36643.
- (238) Alam, M. S.; et al. Involvement of *Salmonella enterica* serovar Typhi RpoS in resistance to NO-mediated host defense against serovar Typhi infection. *Microb. Pathog.* **2006**, *40* (3), 116–25.
- (239) Wang, M.; et al. SufC may promote the survival of *Salmonella enterica* serovar Typhi in macrophages. *Microb. Pathog.* **2015**, *85*, 40–3.
- (240) Hahn, M. M.; Gunn, J. S. *Salmonella* Extracellular Polymeric Substances Modulate Innate Phagocyte Activity and Enhance Tolerance of Biofilm-Associated Bacteria to Oxidative Stress. *Microorganisms* **2020**, *8* (2), 253.

- (241) Zhang, Y.; et al. OxyR positively and directly regulates Vi polysaccharide capsular antigen in *Salmonella enterica* serovar Typhi. *Microb Pathog* 2018, 124, 191–197.
- (242) Christman, M. F.; Storz, G.; Ames, B. N. OxyR, a positive regulator of hydrogen peroxide-inducible genes in *Escherichia coli* and *Salmonella typhimurium*, is homologous to a family of bacterial regulatory proteins. *Proc. Natl. Acad. Sci. U. S. A.* 1989, 86 (10), 3484–8.
- (243) Wilson, R. P.; et al. The Vi capsular polysaccharide prevents complement receptor 3-mediated clearance of *Salmonella enterica* serotype Typhi. *Infect. Immun.* 2011, 79 (2), 830–7.
- (244) Raffatellu, M.; et al. The Vi capsular antigen of *Salmonella enterica* serotype Typhi reduces Toll-like receptor-dependent interleukin-8 expression in the intestinal mucosa. *Infect. Immun.* 2005, 73 (6), 3367–74.
- (245) Wangdi, T.; et al. The Vi capsular polysaccharide enables *Salmonella enterica* serovar typhi to evade microbe-guided neutrophil chemotaxis. *PLoS Pathog* 2014, 10 (8), No. e1004306.
- (246) Dufresne, K.; Saulnier-Bellemare, J.; Daigle, F. Functional Analysis of the Chaperone-Usher Fimbrial Gene Clusters of *Salmonella enterica* serovar Typhi. *Front. Cell. Infect. Microbiol* 2018, 8, 26.
- (247) Hiyoshi, H.; et al. Mechanisms to Evasion of Phagocytosis by Respiratory Burst Arose by Convergent Evolution in Typhoidal *Salmonella* Serovars. *Cell Rep* 2018, 22 (7), 1787–1797.
- (248) Theeya, N.; et al. An inducible and secreted eukaryote-like serine/threonine kinase of *Salmonella enterica* serovar Typhi promotes intracellular survival and pathogenesis. *Infect. Immun.* 2015, 83 (2), 522–33.
- (249) Dong, F.; et al. The malS-5'UTR weakens the ability of *Salmonella enterica* serovar Typhi to survive in macrophages by increasing intracellular ATP levels. *Microb Pathog* 2018, 115, 321–331.
- (250) He, P.; et al. *Salmonella enterica* serovar Typhi plasmid pR ST98 enhances intracellular bacterial growth and *S. typhi*-induced macrophage cell death by suppressing autophagy. *Braz J. Infect Dis* 2012, 16 (3), 262–6.
- (251) Hajra, D.; et al. *Salmonella Typhimurium* U32 peptidase, YdcP, promotes bacterial survival by conferring protection against in vitro and in vivo oxidative stress. *Microb. Pathog.* 2022, 173, 105862.
- (252) Roy Chowdhury, A.; et al. *Salmonella Typhimurium* outer membrane protein A (OmpA) renders protection from nitrosative stress of macrophages by maintaining the stability of bacterial outer membrane. *PLoS Pathog* 2022, 18 (8), No. e1010708.
- (253) Chatterjee, R.; et al. *Salmonella Typhimurium* PgtE is an essential arsenal to defend against the host resident antimicrobial peptides. *Microbiol Res.* 2023, 271, 127351.
- (254) van der Heijden, J.; et al. *Salmonella* Rapidly Regulates Membrane Permeability To Survive Oxidative Stress. *mBio* 2016, 7 (4), No. e01238-16.
- (255) Johansson, C.; Ingman, M.; Jo Wick, M. Elevated neutrophil, macrophage and dendritic cell numbers characterize immune cell populations in mice chronically infected with *Salmonella*. *Microb Pathog* 2006, 41 (2–3), 49–58.
- (256) Gogoi, M.; et al. *Salmonella* escapes antigen presentation through K63 ubiquitination mediated endosomal proteolysis of MHC II via modulation of endosomal acidification in dendritic cells. *Pathog. Dis.* 2018, 76 (2), ftx125.
- (257) Gogoi, M.; et al. *Salmonella* escapes adaptive immune response via SIRT2 mediated modulation of innate immune response in dendritic cells. *PLoS Pathog* 2018, 14 (11), No. e1007437.
- (258) Bermudez-Brito, M.; et al. Cell-free culture supernatant of *Bifidobacterium breve* CNCM I-4035 decreases pro-inflammatory cytokines in human dendritic cells challenged with *Salmonella typhi* through TLR activation. *PLoS One* 2013, 8 (3), No. e59370.
- (259) Won, G.; et al. A *Salmonella* Typhi ghost induced by the E gene of phage phiX174 stimulates dendritic cells and efficiently activates the adaptive immune response. *J. Vet Sci.* 2018, 19 (4), 536–542.
- (260) Wei, L.; et al. *Salmonella enterica* serovar Typhi plasmid impairs dendritic cell responses to infection. *Curr. Microbiol.* 2012, 65 (2), 133–40.
- (261) Wei, L.; et al. Suppression of dendritic cell and T-cell activation by the pRST(9)(8) *Salmonella* plasmid. *Mol. Med. Rep* 2015, 11 (3), 2306–14.
- (262) Salerno-Goncalves, R.; Sztein, M. B. Priming of *Salmonella enterica* serovar typhi-specific CD8(+) T cells by suicide dendritic cell cross-presentation in humans. *PLoS One* 2009, 4 (6), No. e5879.
- (263) Atif, S. M.; et al. *Salmonella enterica* serovar Typhi impairs CD4 T cell responses by reducing antigen availability. *Infect. Immun.* 2014, 82 (6), 2247–54.
- (264) MacLennan, C.; et al. Interleukin (IL)-12 and IL-23 are key cytokines for immunity against *Salmonella* in humans. *J. Infect Dis* 2004, 190 (10), 1755–7.
- (265) Crum, N. F. Current trends in typhoid Fever. *Curr. Gastroenterol Rep* 2003, 5 (4), 279–86.
- (266) Sejvar, J.; et al. Neurologic manifestations associated with an outbreak of typhoid fever, Malawi–Mozambique, 2009: an epidemiologic investigation. *PLoS One* 2012, 7 (12), No. e46099.
- (267) Bisi, S.; et al. Membrane and actin dynamics interplay at lamellipodia leading edge. *Curr. Opin Cell Biol.* 2013, 25 (5), 565–73.
- (268) Chen, Z.; et al. Structure and control of the actin regulatory WAVE complex. *Nature* 2010, 468 (7323), 533–8.
- (269) Cohen, L. A.; et al. Active Arf6 recruits ARNO/cytohesin GEFs to the PM by binding their PH domains. *Mol. Biol. Cell* 2007, 18 (6), 2244–53.
- (270) Hänsch, J.; et al. Molecular dissection of *Salmonella*-induced membrane ruffling versus invasion. *Cell Microbiol* 2010, 12 (1), 84–98.
- (271) Humphreys, D.; et al. Arf6 coordinates actin assembly through the WAVE complex, a mechanism usurped by *Salmonella* to invade host cells. *Proc. Natl. Acad. Sci. U. S. A.* 2013, 110 (42), 16880–5.
- (272) Humphreys, D.; et al. *Salmonella* virulence effector SopE and Host GEF ARNO cooperate to recruit and activate WAVE to trigger bacterial invasion. *Cell Host Microbe* 2012, 11 (2), 129–39.
- (273) Lim, J. S.; et al. Caveolin-1 mediates *Salmonella* invasion via the regulation of SopE-dependent Rac1 activation and actin reorganization. *J. Infect Dis* 2014, 210 (5), 793–802.
- (274) Koronakis, V.; et al. WAVE regulatory complex activation by cooperating GTPases Arf and Rac1. *Proc. Natl. Acad. Sci. U. S. A.* 2011, 108 (35), 14449–54.
- (275) Singh, V.; et al. Arf GTPase interplay with Rho GTPases in regulation of the actin cytoskeleton. *Small GTPases* 2019, 10 (6), 411–418.
- (276) Liu, R.; et al. Wash functions downstream of Rho and links linear and branched actin nucleation factors. *Development* 2009, 136 (16), 2849–60.
- (277) Linardopoulou, E. V.; et al. Human subtelomeric WASH genes encode a new subclass of the WASP family. *PLoS Genet* 2007, 3 (12), No. e237.
- (278) Hanisch, J.; et al. Activation of a RhoA/myosin II-dependent but Arp2/3 complex-independent pathway facilitates *Salmonella* invasion. *Cell Host Microbe* 2011, 9 (4), 273–85.
- (279) Truong, D.; et al. Formin-mediated actin polymerization promotes *Salmonella* invasion. *Cell Microbiol* 2013, 15 (12), 2051–63.
- (280) Westendorf, J. J. The formin/diaphanous-related protein, FHOS, interacts with Rac1 and activates transcription from the serum response element. *J. Biol. Chem.* 2001, 276 (49), 46453–9.
- (281) Nichols, C. D.; Casanova, J. E. *Salmonella*-directed recruitment of new membrane to invasion foci via the host exocyst complex. *Curr. Biol.* 2010, 20 (14), 1316–20.
- (282) Choi, S.; et al. Agonist-stimulated phosphatidylinositol-3,4,5-trisphosphate generation by scaffolded phosphoinositide kinases. *Nat. Cell Biol.* 2016, 18 (12), 1324–1335.
- (283) Watanabe, T.; Wang, S.; Kaibuchi, K. IQGAPs as Key Regulators of Actin-cytoskeleton Dynamics. *Cell Struct Funct* 2015, 40 (2), 69–77.

- (284) Kim, H.; et al. *Salmonella enterica* serotype Typhimurium usurps the scaffold protein IQGAP1 to manipulate Rac1 and MAPK signalling. *Biochem. J.* **2011**, *440* (3), 309–18.
- (285) Brown, M. D.; et al. IQGAP1 regulates *Salmonella* invasion through interactions with actin, Rac1, and Cdc42. *J. Biol. Chem.* **2007**, *282* (41), 30265–72.
- (286) Jolly, C.; et al. The Annexin A2/p11 complex is required for efficient invasion of *Salmonella* Typhimurium in epithelial cells. *Cell Microbiol.* **2014**, *16* (1), 64–77.
- (287) Brooks, A. B.; et al. MYO6 is targeted by *Salmonella* virulence effectors to trigger PI3-kinase signaling and pathogen invasion into host cells. *Proc. Natl. Acad. Sci. U. S. A.* **2017**, *114* (15), 3915–3920.
- (288) Buss, F.; Spudich, G.; Kendrick-Jones, J. Myosin VI: cellular functions and motor properties. *Annu. Rev. Cell Dev. Biol.* **2004**, *20*, 649–76.
- (289) Ono, Y.; et al. Two actions of frabin: direct activation of Cdc42 and indirect activation of Rac. *Oncogene* **2000**, *19* (27), 3050–8.
- (290) Lhocine, N.; et al. Apical invasion of intestinal epithelial cells by *Salmonella typhimurium* requires villin to remodel the brush border actin cytoskeleton. *Cell Host Microbe* **2015**, *17* (2), 164–77.
- (291) Dorsey, C. W.; et al. *Salmonella enterica* serotype Typhimurium MisL is an intestinal colonization factor that binds fibronectin. *Mol. Microbiol.* **2005**, *57* (1), 196–211.
- (292) Fierer, J.; Guiney, D. G. Diverse virulence traits underlying different clinical outcomes of *Salmonella* infection. *J. Clin. Invest.* **2001**, *107* (7), 775–80.
- (293) Smith, R. L.; et al. Magnesium transport in *Salmonella typhimurium*: regulation of mgtA and mgtCB during invasion of epithelial and macrophage cells. *Microbiology* **1998**, *144* (7), 1835–1843.
- (294) Tukel, C.; et al. MarT activates expression of the MisL autotransporter protein of *Salmonella enterica* serotype Typhimurium. *J. Bacteriol.* **2007**, *189* (10), 3922–6.
- (295) Snavely, M. D.; Miller, C. G.; Maguire, M. E. The mgtB Mg²⁺ transport locus of *Salmonella typhimurium* encodes a P-type ATPase. *J. Biol. Chem.* **1991**, *266* (2), 815–823.
- (296) Kiss, T.; Morgan, E.; Nagy, G. Contribution of SPI-4 genes to the virulence of *Salmonella enterica*. *FEMS Microbiol. Lett.* **2007**, *275* (1), 153–9.
- (297) Gerlach, R. G.; et al. *Salmonella* pathogenicity island 4-mediated adhesion is coregulated with invasion genes in *Salmonella enterica*. *Infect. Immun.* **2007**, *75* (10), 4697–709.
- (298) Morgan, E.; et al. Identification of host-specific colonization factors of *Salmonella enterica* serovar Typhimurium. *Mol. Microbiol.* **2004**, *54* (4), 994–1010.
- (299) Knodler, L. A.; et al. *Salmonella* effectors within a single pathogenicity island are differentially expressed and translocated by separate type III secretion systems. *Mol. Microbiol.* **2002**, *43* (5), 1089–103.
- (300) Wang, M.; et al. Molecular Characterization of a Functional Type VI Secretion System in *Salmonella enterica* serovar Typhi. *Curr. Microbiol.* **2011**, *63* (1), 22.
- (301) Maurya, P.; Gulati, A. K.; Nath, G. Status of Vi gene, its expression and *Salmonella* Pathogenicity Island (SPI-7) in *Salmonella* Typhi in India. *Southeast Asian J. Trop Med. Public Health* **2010**, *41* (4), 913–919.
- (302) Wain, J.; et al. Vi antigen expression in *Salmonella enterica* serovar Typhi clinical isolates from Pakistan. *J. Clin. Microbiol.* **2005**, *43* (3), 1158–65.
- (303) Pickard, D.; et al. Composition, acquisition, and distribution of the Vi exopolysaccharide-encoding *Salmonella enterica* pathogenicity island SPI-7. *J. Bacteriol.* **2003**, *185* (17), 5055–65.
- (304) Card, R.; et al. Virulence Characterisation of *Salmonella enterica* Isolates of Differing Antimicrobial Resistance Recovered from UK Livestock and Imported Meat Samples. *Front. Microbiol.* **2016**, *7*, 640.
- (305) Velasquez, J. C.; et al. SPI-9 of *Salmonella enterica* serovar Typhi is constituted by an operon positively regulated by RpoS and contributes to adherence to epithelial cells in culture. *Microbiology* **2016**, *162* (8), 1367–1378.
- (306) Faucher, S. P.; et al. The prpZ gene cluster encoding eukaryotic-type Ser/Thr protein kinases and phosphatases is repressed by oxidative stress and involved in *Salmonella enterica* serovar Typhi survival in human macrophages. *FEMS Microbiol. Lett.* **2008**, *281* (2), 160–6.
- (307) Bouwman, C. W.; et al. Characterization of SrgA, a *Salmonella enterica* serovar Typhimurium virulence plasmid-encoded parologue of the disulfide oxidoreductase DsbA, essential for biogenesis of plasmid-encoded fimbriae. *J. Bacteriol.* **2003**, *185* (3), 991–1000.
- (308) Zhang, Y.; et al. Recognition and Ubiquitination of *Salmonella* Type III Effector SopA by a Ubiquitin E3 Ligase, HsRMA1. *J. Biol. Chem.* **2005**, *280* (46), 38682–38688.
- (309) Miao, E. A.; et al. *Salmonella typhimurium* leucine-rich repeat proteins are targeted to the SPI1 and SPI2 type III secretion systems. *Mol. Microbiol.* **1999**, *34* (4), 850–64.
- (310) Haneda, T.; et al. Genome-wide identification of novel genomic islands that contribute to *Salmonella* virulence in mouse systemic infection. *FEMS Microbiol. Lett.* **2009**, *297* (2), 241–9.
- (311) Shi, L.; et al. Proteomic analysis of *Salmonella enterica* serovar typhimurium isolated from RAW 264.7 macrophages: identification of a novel protein that contributes to the replication of serovar typhimurium inside macrophages. *J. Biol. Chem.* **2006**, *281* (39), 29131–40.
- (312) Vernikos, G. S.; Parkhill, J. Interpolated variable order motifs for identification of horizontally acquired DNA: revisiting the *Salmonella* pathogenicity islands. *Bioinformatics* **2006**, *22* (18), 2196–203.
- (313) Bogomolnaya, L. M.; et al. Form variation' of the O12 antigen is critical for persistence of *Salmonella Typhimurium* in the murine intestine. *Mol. Microbiol.* **2008**, *70* (5), 1105–19.
- (314) Fuentes, J. A.; et al. The *Salmonella* Typhi hlyE gene plays a role in invasion of cultured epithelial cells and its functional transfer to S. Typhimurium promotes deep organ infection in mice. *Res. Microbiol.* **2008**, *159* (4), 279–87.
- (315) Darwin, K. H.; Miller, V. L. The putative invasion protein chaperone SicA acts together with InvF to activate the expression of *Salmonella typhimurium* virulence genes. *Mol. Microbiol.* **2000**, *35* (4), 949–60.
- (316) Jain, K. C.; Mahapatra, A. K. Subdural empyema due to salmonella infection. *Pediatr. Neurosurg.* **1998**, *28* (2), 89–90.
- (317) Kapoor, K.; et al. A rare neurological complication of typhoid fever: Guillain-Barre' syndrome. *J. Pediatr. Neurosci.* **2014**, *9* (2), 148–9.
- (318) Mehndiratta, S.; Rajeshwari, K.; Dubey, A. P. Guillain-Barre syndrome as a complication of typhoid fever in a child. *Neurol. India* **2012**, *60* (4), 433–5.
- (319) May, W.; Senitiri, I. Guillain-Barré syndrome associated with typhoid fever. A case study in the Fiji Islands. *Pac. Health Dialog* **2010**, *16* (2), 85–88.
- (320) Villablanca, P.; et al. *Salmonella* Berta myocarditis: Case report and systematic review of non-typhoid *Salmonella* myocarditis. *World J. Cardiol.* **2015**, *7* (12), 931–7.
- (321) Lauer, B.; et al. Cardiac troponin T in patients with clinically suspected myocarditis. *J. Am. Coll. Cardiol.* **1997**, *30* (5), 1354–9.
- (322) Tong, M. J.; Youel, D. B.; Cotten, C. L. Acute pneumonia in tropical infections. *Am. J. Trop. Med. Hyg.* **1972**, *21* (2), 50–7.
- (323) Cohen, J. I.; Bartlett, J. A.; Corey, G. R. Extra-intestinal manifestations of salmonella infections. *Medicine (Baltimore)* **1987**, *66* (5), 349–88.
- (324) Aguado, J. M.; et al. Pleuropulmonary infections due to nontyphoid strains of *Salmonella*. *Arch. Intern. Med.* **1990**, *150* (1), 54–6.
- (325) Karoli, R.; et al. *Salmonella hepatitis*: an uncommon complication of a common disease. *J. Family Med. Prim. Care* **2012**, *1* (2), 160–2.
- (326) Bhongle, N. N.; Nagdeo, N. V.; Thombare, V. R. A Splenic Abscess which was Caused by *Salmonella* Typhi in a Non Sickler

Patient: A Rare Case Finding. *J. Clin Diagn. Res.* **2013**, *7* (3), 537–538.

(327) Sharavanan, P.; et al. Salmonella typhi Splenic Abscess Following Blunt Abdominal Injury: A Case Report. *J. Clin Diagn. Res.* **2016**, *10* (7), DD01–DD02.

(328) Manjunath, R.; et al. Typhoid-associated acute kidney injury masquerading as a relapse of Takayasu arteritis. *Saudi J. Kidney Dis Transpl* **2017**, *28* (1), 178–180.

(329) Valayatham, V. Salmonella: the pelvic masquerader. *Int. J. Infect Dis* **2009**, *13* (2), e53–5.

(330) Lareau, S. M.; Beigi, R. H. Pelvic inflammatory disease and tubo-ovarian abscess. *Infect Dis Clin North Am.* **2008**, *22* (4), 693–708.

(331) Rohilla, R.; et al. Salmonella osteomyelitis: A rare extraintestinal manifestation of an endemic pathogen. *J. Lab Physicians* **2019**, *11* (2), 164–170.